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INTRODUCTION 
 Multiple drug- resistant tuberculosis
1
 (MDR-TB) is emerging as a 
growing threat to TB control programs in many countries and accounts 
for3.5%of all newly diagnosed  patients worldwide. The potentially serious 
impact of MDR-TB (TB strain resistant to at least   isoniazid and rifampicin) 
has long been recognized; drug resistance is a major threat to tuberculosis 
(TB) control programs worldwide. multidrug resistant TB (MDR-TB) is 
defined as a simultaneous resistant to atleast rifampicin(RMP) and isoniazid 
(INH) patients infected with MDR strains are less chance to be cured from TB 
particularly if they are co-infected with HIV or suffer from other  immuno 
suppressive diseases. MDR-TB is associated with a two to four fold period of 
treatment, psychological problems, economic wastage, poor treatment 
adherence and consequently treatment failure.  
 Globally, 3.5% of new TB cases and 20.5% of previously treated cases 
are estimate to have MDR-TB
2
. In developing countries,due to poverty, 
migration and HIV infection, MDR-TB is associated with spread and 
persistent high incidence. However, the problem is of special concern 
because, expensive treatment, with only 65%-75%efficacy, and may have side 
effects. 
 In perspective of the public health, a study on the identification of risk 
factors linked to MDR-TB at the onset of therapy,among new cases, is 
2 
 
important to identify patients vulnerable to getting infection with MDR-TB 
strains. 
 This is necessary for breaking the transmission cycle of MDR-TB. 
This will further reduce the cost treatment, as well as improve the 
implementation of the DOTS- based RNTCP.  
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REVIEW OF ARTICLES 
 Tuberculosis
3
 is as old as mankind TB is a most common cause of 
death due to a single infectious agent worldwide in adults. In 1993, WHO 
took unprecedented step and declared TB to be a global emergency According 
to recent estimates 10.4 million was infected with mycobacterium 
tuberculosis worldwide. TB
4
 is a principally a disease of poverty with 95% 
cases and 98% of deaths occurring in developing countries. Though disease 
was known since ancient times, organisms causing TB was identified only a 
century ago by Robert Koch on march 24, 1882  Until middle of 20
th
 century 
there was no definitive treatment available for TB till the availability of 
streptomycin, Isoniazid, PAS, in mid 1940‟s predictable curative treatment 
became reality 
EPIDEMIOLOGY 
 It has been estimated prevalence of 2-10 million
5
 TB cases with 2 
million new cases occurring every year. India has the second higher MDR TB 
in the world after chinadrug resistance surveys in several statesindicates 
prevalence of MDR-TB in India 2-3 percent among new cases, about 15-20% 
among re-infection, the RNTCP is scaling up the number of culture and DST 
laboratory nationwide along with treatment .Despite of these achievements 
India‟s efforts to control TB and MDR TB still suffer from few laboratories 
slow diagnostic tools, and inadequate management of treatment. 
4 
 
 India
6
 ranks second in harbouringmultidrug resistant cases out of 
expected 99,000 cases among 50,000 cases are recorded from treated 
pulmonary TB cases. In a study in Hyderabad every three patient among 10 
retreatment cases are being developed having MDR TB who need treatment 
with second the anti-TB drugs. The emergence of résistance to anti-
tuberculosis on general and MDR-TB in particular as became major health 
problem of prime concern  in number of countries and major bottleneck 
ineffective TB control and management of MDR TB is a challenge which 
requires prolonged use of expensive second line drugs with significant 
toxicity
3
mismanagement of MDR-TB may lead to development of extensively 
drug resistant TB, a virtually untreatable TB, which has been recorded in 45 
countries
4
 the economic, social and health status of countries and 
communities could be threatened by virtually untreatable TB among the 
breadwinners, parents and economically productive age. The disease is not 
only medical problem or a public health problem but is also critical social 
problem of great magnitude, Baseline adequate information on 
epidemiological, social, economic cultural factors and their interactions is 
required for its control and effective treatment
4
. 
PULMONARY TUBERCULOSIS 
 Pulmonary TB is the most frequent organ of TB worldwide.  Lungs 
account for a majority of both primary and post-primary forms of TB.  
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Miliary TB invariably affects both lungs symmetrically.Further, Pulmonary 
TB is a major source of infection.  In addition to the elegant studies of Rich 
7
, 
Medlar 
8
 based his observations on 1332 un-excepected deaths in New York 
and further evaluated 17000 necropsy records with reference to Pulmonary 
TB.  The Indian perspective is available from the study based on 1680 
autopsies by Nayak and co-workers at New Delhi 
9
. 
PRIMARY PULMONARY TUBERCULOSIS 
 Classical features of Primary complex in the lung [Ghon complex] are 
a small [usually less than one centimetre] often inapparent parenchymal lesion 
[Ghon lesion or Ghon focus] coupled with enlarged, ipsilateral hilar and less 
commonly  paratracheal nodes.The lymph nodes are generally much larger 
than the parenchymal focus.  As has been repeatedly indicated, the location of 
the parenchymal lesion is usually towards the middle of the lung [upper part 
of the lower lobe or the lower region of the middle or upper lobe depending 
on the side].  Certain sites such as the apical Segment of the lower lobe or 
upper portion of right middle lobe are described as likely sites of primary 
infection, however, no part of the lung is exempt
10
.  
 A single Ghon‟s complex was identified in 58 per cent and multiple in 
16 percent of the cases studied by Medlar
10
.  In one case, five foci were 
identified, one in each different lobe.  In 26 percent cases, the complex was 
incomplete because either a parenchymal or lymph nodal component was not 
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demonstrated.  A typical primary or Ghon‟s focus is single, two millimetres or 
more in size and located within one centimetre of the pleura of the collapsed 
lung.  A majority of the primary foci calcify and a minority show caseous 
necrosis [85% and 15 % respectively].  
 Lymph node enlargement is easily identified in a large majority [87%].  
In order to demonstrate the tubercle, it may be necessary to make serial slices 
in about three-fourths of the cases whereas in the remaining the lesions are 
readily  apparent.  Bilateral adenopathy is uncommon except with left-sided 
primary foci
11
.  Massive lymphadenopathy is reported  especially in the 
poorly nourished. 
PROGRESSION OF TUBERCULOSIS 
 The Natural history of TB in the human host is influenced by age sex, 
mycobacterial virulence, infecting dose, natural and acquired resistance,  
resulting in a tendency of the disease to follow a pattern of progression 
according to Wallgren‟s timetable11. Interplay of these factors and the likely 
mode of spread of the bacillus result in different manifestations.Early in the 
course of, disease, tuberculin conversion after primary infection may result in 
mild illness. In the first few years there is increased susceptibility to military 
spread and meningitis. 
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 Miliary disease and meningitis follow within two to nine months in 10 
per cent of children under two years of age, although these forms can be seen 
at any age.  Segmental lesion [epituberculosis] is an early sequel in infants 
and in a minority of adolescents and young adults generally within two to 
nine months of primary infection.  Pleural effusion,which follow primary TB, 
is also seen as sequel of the Post-primary pulmonary disease. 
 Progression to post-primary TB is more likely if primary infection is 
acquired in the later years of young adulthood than in childhood.  In child 
infection the post-primary disease is delayed until adolescence. Extra-
pulmonary organ TB is variable.  Cervical lymphadenitis may be early but, 
skeletal and renal TB, usually present very late.  This progression is only a 
broad direction and not absolute.  
Further Changes of the Primary Complex 
 The primary complex may heal or progress further.  Progression occurs 
in a small proportion of cases.  Early dissemination is common but may not 
necessarily result in concurrent illness.  The spread of infection from the 
primary lesion is by a variety of ways, such as, direct extension into adjacent 
tissue or by endobronchial, lymphatic or vascular pathways for a disseminated 
spread. 
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 Endobronchial spreal of liquefied caseous material is a cause of 
ipsilateral or contralateral acinar pneumonia.  Implantation of mycobacterium 
in the mucosa of the upper airway can result in laryngotracheal, oral or middle 
ear TB.  Swallowing infective sputum can also lead to TB and ulceration of 
the intestinal mucosa. Ipsilateral hilar lymph node spread is especially 
prominent in primary infections.  Perforation of a bronchus by an enlarged 
caseous lymph node followed by endobronical spread can result in massive 
segmental or lobular pneumonia. From regional lymph nodes bacilli can 
disseminate through lymphatics to the pleura, spine and other viscera.  
Haematogenous disseminations can occur through the thoracic duct after 
lymph node involvement or by direct extension of the lesion into branches of 
the pulmonary vein. 
HEALING 
 Healing of the primary lesions is the rule.  The caseous focus is 
gradually replaced by reticulin and collagen desposition.  Eventually, 
hyalinization, and calcification are common [up to 85%]. Subsequent 
demonstration of these lesions may be difficult.  However, aminority of 
patients may demonstrate radiologically a residual hyalinised scar or 
calcification at the site of the primary [Ghon] lesion, in the lung parenchyma 
and in the hilar or paratracheal lymph nodes a combination referred to as the 
healed primary [Ghon] complex. 
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EARLY GENERALIZATION 
 Early generalization or dissemination is an invariable accompaniment 
of primary TB [detailed above]. The primary infection is accompanied by 
early lymphohaematogeneous spread within hours or days from the site of 
initial implantation
12
.  It is felt that occult mycobcteraemia is probably 
common before acquired immunity and thus may seed many sites in the body 
especially where the bacilli favoured to remain viable
13
. 
 With the sites of these seedings have already been mentioned, one 
aspect needs to be highlighted here.  Huebschmann [1928] 
7
 observed a group 
of nodular lesions in one or both apices of the lung that occasionally follow 
primary TB in children.  These foci are so small that special techniques may 
be necessary to demonstrate them.  These Huebschmann foci heal and cause 
no further disease.  It is likely that Simon foci which are larger, single or 
multiple apical caseous nodules with a tendency to calcification are 
exaggerated form of these smaller foci.  The importance of Simon foci lies  
in the pathogenesis of post-primary TB
7
. Ina minority of the cases 
haematogenous dissemination results in military TB. 
LIQUEFACTION AND PROGRESSIVE PRIMARY TUBERCULOSIS 
 Liquefaction of solid caseous foci is thought to be related to the onset 
of DTH with the release of hydrolytic enzymes by macrophages 
12
.  
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Liquefaction may result in a caseous mass that may include the enlarged 
lymph nodes. Within the liquefied area there are multiplying tubercle bacilli 
and, therefore, there is a risk of transmission of disease.  Due to the 
liqueactive necrosis there is extensive parenchymal destruction and caviation, 
which is generally a little less than the size of the original caseous mass. The 
cavity may communicate with an airway and thus promote bronchial spread to 
other parts of the lung, larynx and the alimentary tract.  An acute fatal 
bronchopneumonia may result. In some of these case the inflammatory 
reaction is neutrophilic, like in the case of bacterial pneumonia, but AFB are 
demonstrable.  
 Due to such a reaction, the diagonosis may be missed. Discharge of the 
liquefied material through the adjacent pleura results in pleural effusion, 
pneumothorax or empyema.  Caseous lymph nodes may similarly discharge 
liquefied contents into the bronchus. 
 Progressive primary TB directly follows the primary lesion.  There 
occurs an extended primary focus or TB bronchopneumonia. cavitation may 
ensue. Cavitaion and progressive primary disease are more likely in infancy, 
at puberty and in the elderly.  There is a tendency for progressive primary TB 
to involve lesions that are apical.  This location is similar to that of post 
primary TB.  
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LOBAR AND SEGMENTAL LESIONS 
 As a consequence of spread along the submucosal lymphatics of 
bronchi, tubercle formation with ulceration of bronchial mucosa at times is 
followed by complete necrosis of the bronchus. Within the bronchus a cold 
abscess may developed and can be seen on the radiograph as a rounded or 
elongated shadow. Bronchial lesions are rare but my result in narrowing of 
the lumen. Extrinsic compression from enlarged lymph nodes in a relatively 
more likely cause of bronchial obstruction. The lobe or segment subtended by 
the obstruction maybe the seat of obstructive hyperinflation, atelectasis, 
secondary (non-TB) pneumonia, TB pneumonia, and disseminated intra-
alveolar epithelioid cell granulomas. Atelectasis most commonly   affects the 
anterior segment of the upper lobes and right middle lobe. Endobronchial TB 
is a complication of primary TB in children 
13
. Residual bronchostenosis and 
bronchiectasis may occur as later complications. 
 Hilar and mediastinial lymph nodes may very rarely cause impaired 
venous return severe enough to cause superior mediastinal syndrome. Such 
lymph nodes may result in tracheal obstruction at the thoracic inlet, rupture 
into mediastinum and pointing abscess into the supraclavicular fossa, erosion 
of blood vessel, invasion of pericardium, compression of or erosion into the 
oesophagus and the formation of various fistulae. 
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EPITUBERCULOSIS 
 Epituberculosis is a rare but more frequent in infants and children than 
in adults. It is a benign lesion appearing as a dense homogenous shadow on 
chest radiographs, typically wedge-shaped, extending from the hilum to the 
pleura. The lesion is frequently large rather sharply defined and has the 
appearance of an area of consolidation. Clinical symptoms are few and the 
shadow generally clears after several months. 
 Residual changes are infrequent and radiographs may show slight 
abnormal marking or calcifications. The radiographic appearance is relatively 
dramatic and sinister, in contradiction that occur in TB. Hence eliasberg and 
newland suggested the term “epituberculosis” which implied a non-
tuberculosis consolidation in a TB lung
7
.The current view is that it is either 
resolving TB pneumonia or an atelectasis produced by obstruction of a 
bronchus by a TB lymph node or by a primary pulmonary lesion.  
 A combination of the two is possible. Since the shape of the shadow is 
highly suggestive of involvement of a portion of lung tissue supplied by a 
bronchus, rich studied several cases and found that a caseous lymph node had 
perforated the bronchial wall, discharge its contents and resulted in aspiration 
of the material. It is understandable that the caseous material is poor bacilli, 
otherwise the lesion would be a progressive bronchopneumonia. The resulting 
consolidation could be partly due to a “hypersensitive” reaction to contents of 
13 
 
the lymph node (a positive “pulmonary tuberculin test, if such a term is 
acceptable).the alveoli in such cases would resemble pneumonia with 
epithelioid cells and few or no AFB. There is also sufficient evidence to 
suggest the atelectasis theory and relief of atelectasis by interventional 
bronchoscope. A combination may occur. Since encroachment by an enlarged 
lymph node is a common accompaniment, therefore, these lesion are common 
in children
7
.                      
PRIMARY TUBERCULOSIS IN ADULTS  
 The radiological and other features of adult primary TB are essentially 
similar to childhood primary disease 
13
.primary TB poses diagnostic problems 
in adults. Prominent hilar and mediastinal glands and caseation are less 
frequent in adults except in patients with AIDS. Also, bronchial obstruction 
and dissemination are less common. As in children, endobronchial  TB may 
occur as a sequelae of adjacent parenchymal disease from which submucosal 
lymphatic spread leads to mucosal ulceration hyper plastic polyp formation or 
fibrostenosis with  atelectasis of the subtended lobe
14
. 
POST PRIMARY PULMONARY TUBERCULOSIS: 
 In contrast to primary TB, the localization of post-primary pulmonary 
TB is a apical or sub-apical. This area has been referred to as the „vulnerable 
region‟ by medlar8. This site probably relate to the relatively higher oxygen 
14 
 
tension in the region resulting from the effect of gravity on the ventilation-
perfussion ratio in the upright lung. Presently, evidence suggests that this is 
possible because of better survival of the bacillus at this region as the higher 
oxygen tension has an unfavourable effect on the macrophage and thereby 
permits intracellular growth
15
. 
 This may also influence progressive primary disease that is more 
frequent in the apical and posterior segments of the upper lobe. Higher 
vascularity and consequently increased oxygen tension may determine the 
preferential multiplication of bacilli at other sites also, such as ends of long 
bones, vertebrae and the renal cortex. 
 Similarly, mitral stenosis, which result in higher pulmonary arterial 
pressure and increased apical blood flow, confers a protective effect. The 
reverse in true for pulmonary stenosis
94
. Lowered blood flow may also be 
associated with decreased lymph flow and thus lesser antigen clearance.  
 The great majority of these cases represent recrudescence of dormant 
tubercle bacilli occurring several years after the primary infection or even 
decades after primary infection. As has been mentioned earlier, there is a 
haematogenous seeding of the apical and sub-apical regions of the lungs, 
following primary infection 
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 This is the endogenous pathway resulting in reactivation TB . 
However, there is evidence to suggest that a bronchial spread from an index 
case may be the route of infection. This is the exogenous pathway resulting in 
re-infection TB. The organisms may reach by either pathways
7
. Infection with 
other related species of myco-bacteria may also have the same result. 
 The pathological lesions seen in post-primary pulmonary TB are 
enumerated in table, based on the findings of Medlar
8
 and Nayak et al
9
. 
LESIONS IN POST- PRIMARY PULMONARY  
TUBERCULOSIS 
 Pulmonary lesions: 
1.Lobular Pneumonia 
      2.Nodular Pneumonia 
                    Small Nodule 
                    Large Nodule 
                    Healed Nodule 
       3.Fibrocaseous Tb 
                     With Cavity 
                Without cavity 
        4.Tuberculosis bronchopneumonia 
 Bronchial lesions: 
         1.Bronchial inflammation 
         2. Endobronchial TB 
         3.Bronchiectasis 
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 Whole lungTB 
 Millary TB 
 Complications: 
           1.Haemoptysis 
           2.Aspergilloma 
           3.Amyloidosis 
           4.Carcinoma 
 5.Oral cavity and upper respiratory tract TB pleural   
 lesions. 
 
EARLY LESIONS 
 The earliest lesion is probably an apical or sub-apical lobular 
pneumonia. These lesions are not well documented because it is believed that 
the pneumonia gives way to a granuloma rapidly. An outline of the alveolar 
reticulin framework in the centre of some of these granulomas may suggest 
such a transition 
9
. 
 It may be mentioned that in 1925, Assmannn drew attention to the fact 
that the earliest lesions clearly visible in clinical TB consist of infiltrates not 
at the apex, nut at the sub-apical and infraclavicular region. These infilitrates  
are known as Assmann infiltrates or foci
5
. The histological counterpart of 
these lesions is not known. 
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NODULAR LESIONS 
 Nodular lesions (coin lesions, tuberculomas) are localized, well-
defined are as of TB wherein the adjacent pulmonary parenchyma is usually 
normal or may show some scarring. A small nodule is less than a centimetre 
in diameter whereas the large nodule is larger than a centimetre in diameter. 
Grossly, nodules are white to yellow in colour and may vary in consistency 
from soft lesions that are largely necrotic to firm or hard lesions that are 
fibrosed or calcified. Small nodules have a central area of caseation, are 
surrounded by epithelioid cells and giant cells and are encapsulated by a 
fibrous wall. Large nodules are similar but show more caseation and less 
encapsulation. Healed nodules are of the size of small nodules and are 
fibrosed or hyalinised or calcified. Anthracotic pigment may be identified in 
any nodule
9
. 
Active nodules especially of the small sixe are predominantly located 
in the apical and sub-apical regions and may be single or multiple. The 
reverse is true for healed nodules. It appears that small nodules give rise to 
larger ones and nodular TB may expand to form fibrocaseous lesions. It may 
be mentioned that (these nodules are not related to Ghon‟s focus. The location 
and the absence of accompanying enlarged lymph nodes should provide a 
clue. Acid-fast bacilli could be demonstrated in seven per cent of small 
nodules and 29 percent of large nodules 
82
. 
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FIBROCASEOUS TUBERCULOSIS 
 Fibrocaseous TB includes lesions that reveal well known features of 
TB such as caseation, consolidation, liquefaction and fibrosis. Grossly, 
various patterns are seen. The apical and posterior segments of the upper 
lobes are predominantly involved. Lymph node involvement is slight in 
comparison to primary TB. Retraction of lung parenchyma is associated often 
with pleural thickening. In some cases the lung may have an appearance of 
bronchopneumonia due to consolidation. At times the caseous areas stand out 
amidst the black background of antharacotic pigmentation. The most striking 
feature is the presence of one or more cavites. Cavities may assume varying 
sizes and may be so large as to result in a severe loss of lung paraencyma. The 
wall of the cavity  may be lined by TB granulation tissue or show varying 
fibrosis. 
 Often the thick walls of cavities seen on radiographs are found to be 
accounted for by a rim of consolidation of the adjacent lung. Communication 
may or may not have been established with a bronchus. These findings have 
implications on auscultation of the chest process allows the arteries to 
obliterate. The caeseous material may Traversing the wall or the lumen along 
fibrous bands, are bronchi and branches of pulmonary artery. Fortunately in 
most instances the chronic soften the wall of the arteries giving rise to 
19 
 
Rasmussen‟s aneurysms. These may give rise to haemoptysis that may be 
fatal. 
 Microscopically variable caseous necrosis, extensive fibrosis, 
numerous palisades of epithelioid cells and fibroblasts together with 
Langhans giant cells are seen. Areas of consolidation may show caseous 
pneumonia or even a neutrophilic response. Microscopic cavities may be 
identified in such pneumonic foci. Cavities are lined by necrotic TB 
granulation tissue and show fibrosis. Occasional cavities may be lined in part 
by columnar or squamous epithelium. Acid-fast bacilli can be demonstrated 
more frequently in fibrocaseous lesions than in nodular TB. Acid-fast baclilli 
were found more frequently in cavitary lesions (88%) in comparison to non-
cavitary lesions (77%)
5
. 
Smaller cavities may heal. Healing in general results in fibrosis and 
cicatrisation extending between the upper pole of the hilum and the apex, thus 
elevating the hilum on that side. This causes volume loss on the ipsilateral 
side. Simultaneously the upper mediastinum would be pulled towards the side 
of the lesion distorting the trachea and giving a characteristic radiological 
appearance. Modern treatment, however, allows rapid closure of cavities, 
which leaves little evidence of disease on chest radiographs. Serious 
complications resulting from pulmonary TB are uncommon now except when 
the disease has been neglected and becomes chronic and progressive. 
20 
 
OTHER LESIONS 
 Tuberculosis bronchopneumonia and military TB are a consequence of 
a large dose of virulent organisms disseminating through the bronchus or the 
blood stream, respectively. It is obvious that the host immunity may be 
compromised. The lesions have been described earlier. 
BRONCHIAL LESIONS 
 Despite being closely associated with the lung parenchyma, bronchi 
not appear to be frequently affected in pulmonary TB
19
. In a majority of cases, 
the inflammation is non-specific and typical granulomas may not be seen. In 
some cases endobronchial TB, as discussed under primary pulmonary TB, 
may follow post-primary lesions 
20
 and this is characterized by bronchial 
inflammation ulceration, granuloma, small pseudopolyps and eventual healing 
by fibrosis. Bronchostensosis may give rise to post-stenotic dilatation of the 
bronchus. 
 Bronchiectasis directly attributable to pulmonary TB is rare. In those 
instances when this is found it usually occurs in the upper lobe and is 
relatively asymptomatic. Along with bronchostensosis it predisposes to 
secondary infection, haemoptysis and atelectasis. 
 Extension of TB to the pleura is common. Pericardial TB may follow 
pleuritis or by lymphatic spread from a pulmonary focus. 
21 
 
CHRONOLOGY OF IMMUNOPATHOGENESIS OF 
TUBERCULOSIS 
 Pulmonary TB 
20,21
can be marked with four distinct phases following 
mycobacterium tuberculosis infection. Each of these phases determined by the 
homeostasis between the bacillary factors and host immune status including 
both innate and adaptive immunity (cellular as well as hormonal). First, 
following inhalation of mycobacterium tuberculosis, depending on their 
intrinsic microbicidal capability alveolar macrophages ingest the pathogen 
and destroy them. However, bacilli often evade initial destruction by 
phagocytes and continue to multiple inside them ending in their disruptions to 
cause fresh infection of the bystander macrophages. 
 This heralds the second phase, characterized by recruitment of blood 
monocytes and other inflammatory cells to the primary disease site, the lung 
in most instances. Monocytes ingest the bacilli and differentiate into 
macrophages, but fail to eliminate there completely. This stage is marked by 
logarithmic growth of the pathogens with little tissue destruction. Following 
this, antigen specific T-cell are recruited to  that activate the monocytoid cells 
leading to  either of these two types of gaint cell epitheliod and mult-nucleted 
langhans‟ type gaint cells. This is the third stage of granuloma formation, 
which aims at walling off the infection from the rest of the body and prevent 
dissemination of bacilli, thus contains infection. This stage of latency, which 
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disruptsunder conditions of failing immune surveillance and give rise to 
endogenous reactivation of dormant foci culminating in post-primary TB 
which is characterized by cessation necrosis (fourth phase). In summary, after 
entry into the body, mycobacterium tuberculosis encounters a series of host 
defense mechanisms with final outcome depending on the balance between 
bacillary growth and extent of host immunity. Essentially, all these phases of 
TB infection involve various arms of innate and acquired immunity 
sequentially in an orchestrated manner.  
MECHANISM OF DRUG RESISTANCE: 
 Tuberculosis cavity usually contains 10
7
 to 10
9
 bacilli. Mutations 
causing resistance to isoniazid occur in about 1 in 10
6
 replications, and the 
mutations causing resistance to rifampicin occur in about 1 in 10
8
 
replications,and the overall the probability of spontaneous mutations causing 
resistance to both isoniazid and rifampicin would be 10
6
 x 10
8
 which is equal 
to 1 in 10
14
 replications. Patients with extensive cavitary pulmonary TB, the 
chance of the development of spontaneous dual resistance to rifampicin and 
isoniazid is very common and this forms the basis for administration of 
multiple drugs for the treatment of TB. 
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MOLECULAR BASIS OF MULTIPLE DRUG-RESISTANCE 
 Predominantly, the molecular basis of drug resistance could be traced 
to mutations in genes coding for drug target proteins 
23
. However, as an 
efficient pathogen, mycobacterium tuberculosis is equipped with several 
defence strategies, including a complex cell wall, drug efflux pumps and 
multi-functional proteins.  
RIFAMPICIN 
 Resistance of rifampicin is a relatively rare event
24
 and leads to 
selection of mutants that are already resistant to other components of shout-
course treatment. Therefore, rifampicin resistance is often regarded as an 
excellent surrogate marker for MDR-TB. The association of the ribonucleic 
acid (RNA) polymerase beta subunit gene (rpoB) with resistance to rifampicin 
has been documented previously and subsequent reports from various groups 
have confirmed this association in clinical isolates of mycobacterium 
tuberculosis. Introduced in the early 1970s, rifampicin is a lipophilic 
ansamycin and its efficacy as an antituberculosis drug lies in its ability to 
diffuse across the hydrophobic cell envelope 
24
. The „ansa‟ designation 
denotes an aromatic centre that is bridged on both the ends by an aliphatic 
chain. The conformational relationship between the aromatic nucleus and the 
aliphatic chains is very important for microbiological activity, probably 
because of the interaction of the drug with its target. 
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 It is a potent inhibitor of DNA dependent RNA polymerase. The RNA 
polymerase is a multisubunit protein consisting of a core enzyme having four 
polypeptide chains. The holoenzyme has an additional subunit delta that 
allows promoter recognition for initiation of transcription. The subunits alpha, 
beta, beta‟ and delta are coded by the rpoA, rpoB, rpoC and rpoD genes, 
respectively). Rifampicin binds to the beta subunit involved in the initiation 
and elongation of transcription. 
RIFAMPICIN RESISTANCE 
 The molecular mechanism of rifampicin resistance has been thorough 
studied in Escherichia Coli and supplemented with genetic studied in early 
1980s .mutation occurring in a discrete region of rpoB gene were identified 
and correlated with rifampicin resistance by several investigators 
25
. This 
agnate region of mycobacterium tuberculosis rpoB was first cloned and 
sequenced by Telenti et al 
26
 on the basis of sequances information available 
from rpoB gene of mycobacterium leprae 
26
.  
 They identified a total of 15 distinct mutations clustered in a 23-amino 
acid stretch (69 bases).of the 15 mutations,eight were in the conserved amino 
acid residue 526 or 531 of the rpoB gene. Kapur et al 
26
 sequenced 121 
rifampicin-resistant strains and   concluded that 90 % of the rifampicin-
resistant strains had sequence alteration in the 69 base pair(bp) hotspot that 
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was present within the 350 bp region showing considerable polymorphism 
amongst the rifampicin-resistant strains. 
 These earlier efforts led to a surprising discovery that certain mutations 
were relatively more abundant in one set of population than the other,and 
pointedto geographic partitioning and strain divergence amongst the 
rifampicin-resistant strains. Subsequent work has documented several other 
novel mutations that have been added to the list of mutations in the rpoB gene 
in rifampicin-resistant strains. 
  A study from Japan
27
 established for the first time a relationship of 
these mutations to the level of resistance demonstrated by the strains. Isolates 
with mutations in codons 513,526,and 531 had high levels of drug resistance 
indicated by minimum inhibitory concentration (MIC) levels of greater than 
or equal to 50 microgram/ml. In contrast, amino acid substitutions located at 
position 514,521 or 533 resulted in low-level resistance (MIC<TO 
12.5microgram/ml). It is important to mention here than in some of the 
rifampicin- resistant strains studied earlier, no mutation either in the rpoB 
hotspot or its flanking region were found, suggesting that there must be 
supplementary molecular mechanisms associated with the rifampicin-
resistance. 
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ISONIAZID 
Isonicotonic acid hydrazide (isoniazid), one of the key drugs for the 
treatment of TB is considered to be an ideal antimicrobial agent because of its 
low cost, excellent intracellular penetration, bioavaibility, and a narrow 
spectrum of action. 
ISONIAZID RESISTANCE 
 Isoniazid is a pro-drug and is converted into active yet an unstable 
eletrophilic intermediate that inhibits the biosynthesis of cell wall mycolic 
acids. It was observed  that complete deletion of katG led to the development 
of high-level resistance (MIC>50microgram/ml). furthermore, it was found 
that a subset of isoniazid-resistant strains of  mycobacterium tuberculosis had 
intact katG.24 isoniazid-resistant isolates were analysed for insertions, 
deletions and substitution mutations in the katG locus. The mutations in the 5‟ 
region. 
STREPTOMYCIN 
 The antibiotics aminoglycosides, macrolides and tetracylines target 
translation machinery of the pathogen. Streptomycin is an aminocyclitol 
glycoside that binds to 16S ribosomal RNA (rRNA OPERONS including 16S 
rRNA, and therefore mutations in one copy can be compensated by the active 
products of other copies. But slow growing mycobacteria like mycobacterium 
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tuberculosis or mycobacterium leprae have a single copy of 16S rRNA, 
implying that any mutation in these genes would confer resistance to 
streptomycin
28
. 
 It is importance in mycobacterium tuberculosis arises due to alteration 
of the target than drug itself. Mutations in two target genes are associated with 
streptomycin resistance in mycobacterium tuberculosis, the 16S rRNA and 
ribosomal protein S12. The latter is involved in the translation machinery 
indirectly where it stabilizes the quaternary „pseudoknot‟ structure of 16S 
rRNA Therefore, any mutation in 12 can result in altered structure of 16S 
rRNA preventing binding of streptomycin, thus, conferring resistant. 
PYRAZINAMIDE 
 Pyrazinamidase led to the discovery of mycobacterium tuberculosis 
pyrazinamidase (pnc A)that had both pyrazinamidase and nicotinamidase 
activate. The mutations mapped onto mycobacterium tuberculosis pncA from  
clinical isolates, nucleotide insertions and deletions. 
FLUOROQUINOLONES 
 Fluoroquinolones target the bacterial DNA gyrase, an ATP- dependent 
type II DNA topoisomerase that catalyses the negative supercoiling of DNA. 
This enzymes is made up of four units(alpha2 beta2)that are encoded by the 
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gyr A and gyrB  genesrespectively. Fluoroquinolones bind to the gyrase and 
inhibit the supercoiling of DNA. 
MOLECULAR MECHANISM UNDERLING ANTITUBERCULOSIS 
DRUG RESISTANCE 
SL.NO. DRUG 
GENES INVOVLED IN 
RESISTANT 
1. Group 1 first-line oral 
antituberculosisagents isoniazid 
Enoyl acly carrier protein 
(acp)reductase (inhA), catalase-
peroxidase (katG),alklyl 
hydroperoxidase reductase 
(ahpC), oxidative stress 
regulator(oxyR) beta-ketocyl 
carrier protein systhase (kas A) 
2. i)Rifampicin 
ii)Pyrazinamide 
iii) ethambutol 
i)RNA polymerase subunit 
B(rpoB) 
ii)Pyrazinamidase (pncA) 
iii)Aabinosyl transferase (emb 
A,   emb B, and emb C) 
3. Group 2 injectable 
antituberculosis agents 
streptomycin  
Ribosomal protein subunit 12 
(rpsl) 16s ribosomal RNA (rrs), 
aminoglycoside 
phosphotransferase gene (strA) 
4. i)capreomycin 
ii)Group 3 fluoroquinolones 
i)haemolysin(tlyA) 
ii)DNA gyrase (gyr A and gyr 
B). 
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 Since Robert Koch‟s discovery of mycobacterium tuberculosis in 
1882, microscopic detection of the bacilli in clinical specimens has remained 
the mainstay of tuberculosis diagnosis in developing nations. However, in 
human immunodeficiency virus (HIV) era microscopic diagnosis has certain 
drawbacks (i) a low clinical sensitivity of the technique in HIV-associated 
TB; and (ii) lack of access to quality microscopy services in HIV endemic 
areas. 
Recently, a number of exciting technologies are being developed for 
rapid and improved diagnosis of TB including HIV-associated TB. These 
include improvements in microscopy, growth-based detection and subsequent 
strain characterization including drug susceptibility testing (DST), antigen 
detection, molecular detection and recently described interferon release assays 
(IGRAs). 
CLINICAL SPECIMENS: COLLECTION AND TRANSPORTATION 
 In pulmonary TB, sputum is the specimen of choice. If TB of any other 
organ of the body is suspected, specimen should be from specific organ or 
system such as urine for renal TB and cerebrospinal fluid (CSF) for TB 
meningitis. Mycobacterium tuberculosis is in abundance in lesions showing 
rapid caseation. 
 
30 
 
Sputum 
 The specimen is collected in a sterile container. It is a common 
misassumption that as mycobacterial specimens are decontaminated before 
culture, cleanliness of the container is not important. Unsterilized containers 
may be contaminated with environmental mycobacteria. 
 To facilitate the choice of container, following sp0ecifications are 
recommended for a container: (i) widemouthed so that the patient can 
expectorate easily inside the container without contaminating it from outside; 
(ii) volume capacity of approximately 25 ml; (iii) made of transparent 
material in order to observe specimen volume and quality without opening the 
container; (iv) screw capped to obtain a water-tight seal, to reduce the risk of 
leakage during transport; (v) easily-labeled to allow p0ermanent 
identification; and (vi) rigid, to avoid breakage during transit. 
 An ideal container is the 28 ml universal container, which is a heavy 
glass, screw capped bottle. This container is reusable after thorough cleaning 
and sterilization. The identification number can be permanently engraved on 
the bottle cap. 
 In TB diagnosis, care must be taken to obtain adequate and satisfactory 
specimens to the laboratory are important to ensure that the results are 
accurate and reliable. 
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Collection Procedure 
 It is best to obtain a sputum specimen early in the morning before the 
patient has eaten, since food particles in smears make them difficult to 
examine
29
. For collecting a good sputum specimen, the patient must be given 
clear instructions 
2
. Aerosols containing mycobacteria may be formed when 
the patient coughs to produce as sputum specimen. Patients should, therefore, 
produce specimens either outside in the open air or away from other people 
and not in confined spaces such as toilets. 
 Because of the intermittent excretion of tubercle bacilli, three 
specimens should be collected for diagnosis as follows: (i) one spot specimen 
when the patient first attends the health service; (ii) one early morning 
specimen (preferably the next day); (iii) one spot specimen when the early 
morning specimen is being submitted for examination. These should not be 
pooled but should be sent to the laboratory as separate specimens. 
 If a patient has a productive cough, obtaining a sputum specimen is a 
fairly straightforward procedure. The patient is given a container on his first 
attendance. He should be instructed with demonstration by actual actions such 
as: (i) to inhale deeply two to three times; (ii) to cough out deep from the 
chest; (iii) to open the container and spit the sputum into the bottle; (iv) to 
avoid saliva or nasal secretions; and (v) to close the container. 
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 A good sputum specimen should be thick, purulent and of sufficient 
quantity at least 5 ml. The details of the patients name, address, age, sex and 
bottle number are to be recorded in a form/card and sent to the laboratory with 
the specimen. Specimens should be transported to the laboratory as soon as 
possible after collection. If refrigerated or kept in as cool a place as possible 
to inhibit the growth of unwanted micro-organisms. If refrigerator is not 
available and specimen is to be transported in hot climate then it should be 
preserved by adding equal volume of one per cent acetyl pyridinium chloride 
in two percent saline. 
Collection of Specimens Other Than Sputum 
Fibreoptic Bronchoscopy 
 Fibreoptic bronchoscopy has been extensively used to ascertain the 
diagnosis in patients who produce inadequate sputum or do not produce 
sputum at all, and in those with smear-negative  pulmonary TB. Various 
bronchoscopic specimens such as bronchial washings, brushings, 
bronchoalveolar lavage (BAL) fluid and transbronchial lung biopsy have been 
evaluated and found to be useful 
30
. 
Gastric Lavage 
 Gastric Lavage has often been used for the diagnosis of pulmonary TB 
in young children instead of sputum. Young children seldom produce 
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adequate sputum and secretions from the respiratory tract are often 
swallowed. Gastric lavage reveals the organism in 30 to 40 percent of the 
cases and the yield may be greater in infants with extensive disease
31
 
 Gastric lavage should be performed early in the morning, when the 
patient has been fasting for the preceding eight hours. Securing the specimen 
at this time would minimize the dilution of the bronchial secretions 
swallowed during the night by saliva or tears. Inhalation of superheated 
nebulized saline prior to gastric lavage has been reported to increase the 
bacteriologic yield. 
 Following insertion of nasogastric tube, the stomach contents are 
aspirated. Then a small amount of sterile distilled water, (not more than 50 to 
70 ml), is instilled through the nasogastric tube and the aspirate is added to 
the first collection. As gastric acidity is poorly tolerated by Mycobacterium 
tuberculosis, the gastric aspirate should be immediately neutralized either 
with 10 percent sodium carbonate added by dropper to just pink (pH7) 
indicated by phenol red, or with 40 percent anhydrous sodium phosphate to 
green with bromothymol blue as an indicator. 
Urine 
 The first few milliliters of urine should be allowed to flush the external 
urethra. Thereafter, clean-voided total volume of the first early morning urine 
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specimen on three consecutive days is collected in a sterile container and 
transported to the laboratory as early as possible. 
Cerebrospinal Fluid 
 About 5 to 10 ml of CSF should be collected for culture in a sterile 
vial. 
Serous Fluids 
 The largest possible volume of pleural, pericardial, synovial and 
ascetic fluid is procured for culture and 1 ml of 3.8 percent sodium citrate 
solution per 4 ml of specimen or 1 ml of 1:1000 heparins per 50 ml of fluid is 
added to prevent clotting of the serous fluid. 
Tissue 
 Tissue biopsy specimens of lymph nodes, liver etc., are aseptically 
collected in a viral containing normal saline and transported to the laboratory 
immediately. Tissue in formalin should never be sent for culture. 
 Pus and bronchial secretions should be collected in sufficient quantities 
when possible to enable the concentration of mycobacteria. Bone marrow 
aspirates, which are generally free of rapid growing non-acid fast bacteria, 
can be directly inoculated on to the Lowenstein Jensen (L-J) medium. 
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 Urine, CSF, Synovial or other fluids which are collected aseptically 
need to decontamination. For other specimens, sodium hydroxide in the final 
concentration of two percent in the diluted specimen is the most commonly 
used liquefying agent and digestant. The decontaminated specimen is 
concentrated by sedimentation in a refrigerated centrifuge at 3000 g for 30 
minutes. The sediment is used for inoculating media and preparation of 
smears while the supernatant can be used for biochemical and/or 
immunological investigations. 
DIRECT DEMONSTRATION OF MYCOBACTERIA BY STAINING 
TECHNIQUES 
 Use of microscopy in diagnosis of TB is of paramount importance, as 
culture takes a long time before the results are ready. Microscopy is also 
helpful in the detection of open or infectious cases. Stained smears are 
examined directly from the sputum and after concentration 
32
. 
 The tubercle bacilli are gram positive though they do not take the stain 
readily. Mycobacteria retain the primary stain even after decolourization with 
acid alcohol; hence the term “acid fast”. A counter-stain is employed to 
highlight the stained organisms for easier recognition. There are several 
methods of determining the acid fast nature of mycobacteria. In the carbol-
fuchsin (Ziehl-Neelsen) procedure, acid fast organisms appeared against a 
blue background. 
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 Acid fastness is based on the integrity of the cell wall beaded or barred 
forms are frequently seen in Mycobacteruium tuberculosis while 
Mycobacteruium bovis stains more uniformly. In younger cultures, no acid 
fast rods and granules have been reported.  
 The mycobacterial cell wall is complex in nature. It has high lipid 
content, which accounts for about 60 percent of the cell wall weight. The cell 
wall has several distinct layers.  The inner layer overlying the cell membrance 
is composed of peptidoglycan (murein). 
 External to the murein is a layer of arabinogalactan, which is 
covalently linked to a group of long chain fatty acids termed mycolic acid, 
This form a dense palisade, arranged in rope like structure, which gives the 
cell wall its thickness and is largely responsible for acid fastness. 
 It has been shown that at least 10000 bacilli per ml of sputum are 
required for direct microscopy to be positive. The sensitivity can be further 
improved by examining more than one specimen form a patient. 
 Examination of two specimens will, on an average, detect more than 
90 percent of cases and the addition of a third specimen increases the 
percentage to approximately 95 to 98 percent. A negative smear, however, 
does not exclude the diagnosis of TB as some patients harbor fewer numbers 
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of bacilli which cannot be detected by direct microscopy. A poor quality 
specimen or smear may also produce negative results. 
New glass slides should be used for making smears as acid fast 
bacilli(AFB) are not always removed from the old slides. Only those reagents 
and diluents should be used which have been shown to be free of 
environmental mycobacteria to avoid false positive smears. Direct 
examination is performed by selecting a purulent looking portion of sputum 
and spreading it thinly on a glass slide with a bacteriological loop or a 
wooden stick. 
 The watery part of sputum is less likely to contain bacilli. The AFB are 
seen as bright red rods against the blue, green or yellow background 
(depending upon the counterstain used in staining). A negative result does not 
exclude TB. As recommended by World Health Organization (WHO), before 
declaring a slide negative it is essential that at least 100 fields are examined 
taking over at least 10 minutes. Smear can be graded according to the number 
of bacilli seen. 
OTHER STAINING METHODS USING CARBOL FUSHSIN 
 Other staining methods using carbol fushsin for light microscopy 
include the cold staining methods (such as, kinyoun‟s or with Gabett‟s 
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solution). The performance of these techniques might have been 
overestimated. 
 Carefully planned studies have shown that the quantity of bacilli seen 
with a cold stain method is generally less than that with the conventional 
Ziehl-neelsen(Z-N) staining method, which might pose a problem in 
paucibacillary specimens.  
The Gabett‟s solution has advantage only for experienced technicians 
who have to stain large numbers of smears, since it consists of only two steps 
(acid and methylene blue combined). However, the background colour with 
this method with this method is often not satisfactory. 
GRADES ACCORDING TO THE NUMBER OF BACILLI SEEN 
WITH ZIEHL-NEELSEN STAINING: 
NO.OF AFB FIELDS REPORT 
None Per 100 oil immersion 
field 
Negative 
1-9 Per 100 oil immersion 
field 
Scanty(report exact 
number) 
10-99 Per 100 oil immersion 
field 
1+ 
1-10 Per oil immersion 
field(examine 50 fields) 
2+ 
>10 Per oil immersion field 
(examine 20 fields) 
3+ 
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FLUORESCENT STAINING 
 Ziehl-Neelsen staining is a time consuming process for staining as well 
as examination. The WHO has recommended that the maximum number of  
Z-N smears examined by a microscopist in a day should not exceed 20. If 
more than this number of examinations is attempted, visual fatigue will lead 
to a deterioration of reading quality 
 On the other hand, proficiency in reading the Z-N smears can only be 
maintained by examination at least 10-15 Z-N smear per week,i.e., an average 
of two to three smears per day. 
 Establishment of fluorescence microscopy is recommended where 
more than 50 smears are examined per day, and if electricity is continuously 
available. Under such circumstances fluorescence microscopy might be cost-
effective. Additional requirements in training and economic considerations 
(capital investment and maintenance) need to be taken into account before 
introducing fluorescence microscopy. 
 Fluorescence staining utilizes basically the same approach as Z-N 
staining, but carbol fuchsin is replaced by a fluorescent dye (auramine-O, 
rhodamine, auramine rhodamine, acridine orange etc.), the acid for 
decolourisation is milder and the counterstain, though not essential, is useful 
to quench background fluorescence. 
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 Both sensitivity and specificity of fluorescence microscopy are 
comparable to the characteristics of the Z-N technique. The most important 
advantage of the fluorescence technique is that the slides can be examined at a 
lower magnification, thus allowing the examination of a much larger area per 
unit of time. In fluorescence microscopy, the same area that needs 
examination for 10 minutes with a light microscope can be examined in two 
minutes. 
 To increase the sensitivity of microscopic examination, various 
methods for concentrating the bacillary content of sputum and other clinical 
specimens are used. The most widely used method which concentrates the 
bacilli without inactivating them is Petroff‟s method 
PETROFF’S METHOD 
 In this method, the sputum is incubated with an equal volume of four 
percent sodium hydroxide at 37 degree C with frequent shaking till it becomes 
clear. This takes an average of 15 to 20 minutes. It is centrifuged at 3000 rpm 
for 30 minutes. The deposit is neutralized with dilute hydrochloric acid using 
neutral red as an indicator. This deposit can be used for making microscopy, 
culture and other diagnostic tests. 
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Value of Smear Examination in Extra-pulmonary Specimens 
 Specimens form extra pulmonary sources, such as urine, CSF and other 
body fluids are centrifuged and the deposit is stained and examined. 
 The benefit of microscopy in these specimens is limited because of 
their paucibacillary nature and it is, therefore, recommended that the extra-
pulmonary specimens be referred for culture and other molecular techniques. 
Gastric Washings 
 Examination of direct smears of gastric lavage should be avoided, as 
the results could be misleading, The AFB are frequently present in food and 
water and hence in the stomach. There is no way of distinguishing such 
organisms from tubercle bacilli on microscopy and positive results must be 
regarded with suspicion. 
Laryngeal Swabs 
 Direct smear examination of laryngeal swabs is not much useful. A 
negative result cannot rule out TB and whenever possible, the material 
obtained should be subjected to mycobacerial culture. 
Pus and Thick Aspirates 
 Direct smears of pus and other body fluids, should be made thin. Thick 
smears tend to float off the slide and even if they are retained, the AFB may 
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be difficult to see after staining. Problems may arise if a large amount of 
blood is present in the specimen since blood may sometimes produce acid fast 
artifacts. 
Pleural and Pericardial Fluid 
 The pleural and pericardial fluids should be centrifuged and smears 
should be prepared from the sediment. Again, these should be thin otherwise 
they may float off the slide. 
Cerebrospinal Fluid 
Smears from CSF are rarely positive and sediment from the CSF 
should rather be cultured. If a smear is desired, two parallel marks about 10 
mm long and 2 mm apart should be made on a clean glass slide. A loopful of 
the sediment is spread between these marks are the smear is allowed to dry. 
Another loopful of the sediment is then spread over the first. When this is dry, 
the process may be repeated depending on how much sediment is available. 
This procedure clearly marks the area to be searched for AFB. It is desirable 
that two independent readers examine the smears. The clots should be saved 
for culture. 
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Urine 
 Smears of centrifuged urine deposits are most unreliable and should be 
avoided. Non-tuberculous mycobacteria (NTM) are sometimes present in the 
urine, either when it is voided or as a result of poor collection techniques. The 
presence of AFB in urine should be viewed with suspicion. 
Isolation of Mycobacteria By Culture 
 Culture examination, on the other hand, detects fewer bacilli and 
increases the number of TB cases found, often by 30 to 50 percent. Culture 
methods provide definitive diagnosis by establishing the viability and identity 
of the organisms. Further, in order to distinguish between different 
mycobacterial species as well as to perform drug susceptibility tests, culture 
examination becomes a necessity. 
 Compared to other bacteria, which typically reproduce within minutes, 
Mycobacterium tuberculosis proliferates extremely slowly (generation time 
18 to 24 hours). Further, growth requirements of mycobacteria are such that 
they will not grow on primary isolation in simple chemically defined media. 
Hence, culture methods for mycobacteria are expensive and require 
considerable infrastructure and technical expertise. 
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Cultures are very sensitive for the detection of tubercle bacilli and may detect 
as few as 10 to 100 bacilli per ml of sputum. The culture is considered as gold 
standard . Most commonly used medium is L-J medium. It contains eggs, 
asparagines, glycerol and some mineral acids. 
Cultural Characters 
 The growth appears in about two weeks but may be delayed up to six 
to eight weeks. Optimum temperature for growth is 37 degree C; growth does 
not occur below 25 degree C and above 40 degree C. Optimum PH for growth 
is 6.4 to 7.0. Increased carbon dioxide (CO2) tension (5% to 10%) enhances 
growth. Human strains grow more luxuriantly in culture (eugenic) than do 
bovine strains (dysgenic). The addiction of a low percentage of glycerol to the 
medium encourages the growth of human strains but not that of bovine 
strains, which may in fact be inhibited. 
Culture Media 
 Various types of media are commonly used have been summarized  
Colony Characteristics 
 On solid media human type of tubercle bacilli give rise to discrete, 
raised, irregular, dry and wrinkled colonies which are creamy white to begin 
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with and then develop buff colour. By contrast, the bovine type grows as flat, 
white, smooth, moist colonies which “break up” more readily when touched. 
 Tubercle bacilli will grow on top of liquid medium as a wrinkled 
pellicle if the inoculums is carefully floated on the surface and flask left 
undisturbed otherwise they will grow as floccules throughout the medium. 
However, a diffuse growth can be obtained by adding a wetting agent such as 
Tween 80. Virulent strains tend to form long serpentine cords in the liquid 
media while virulent strains grow in a more dispersed fashion. 
 The clinical specimen as such, or after concentration, is inoculated 
onto two bottles of L-J medium and incubated at 37‟C. Cultures are examined 
initially after three to four days to rule out the presence of rapid growing 
mycobacteria and contaminant fungi and bacteria. Thereafter, cultures are 
examined twice weekly. A negative result is given, if no growth appears after 
eight to twelve weeks. If growth is obtained, then a Z-N stained smear made 
from the same is examined and routine biochemical tests put up. 
 All cultures should be examined 18 to 72 hours after inoculation to 
detect gross contaminants. Thereafter cultures are examined weekly, up to 
eight weeks on a specified day of the week. With doubtful cultures, the acid-
fastness should be confirmed by Z-N staining. A very small amount of growth 
is removed from the culture using a loop and gently rubbed into one drop of 
sterile saline on a slide. 
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 At this point the ease with which the organisms emulsify in the liquid should 
be noted; as tubercle bacilli do not form smooth suspensions, unlike some 
other mycobacteria. The smear is allowed to dry, fixed by heat and stained by 
the Z-N method. 
Animal Inoculation 
 Guinea pig inoculation was once a popular way of diagnosing TB but 
should now be regarded as obsolete. It has been clearly demonstrated that the 
use of this animal offers no practical advantage over in vitro culture. In 
addition to human considerations, animal inoculation is costly and generates 
many biohazards. However, in some laboratories it is still used.  
Immunodiagnosis 
Antibody detection tests: 
 Various antigens have been evaluated for detection of antibody to 
mycobacterium tuberculosis. The A60 is the most extensively used antigen 
for both pulmonary and extrapulmonary, adult and childhood TB. 
Immunoglobulin(Ig) G (IgG) and IgM detection has been evaluated. In 
various studies the sensitivity of these tests has ranged between 30 to 100 % . 
A variety of commercial kits are available primarily in developing countries. 
However, all them lack adequate sensitivity and specificity. 
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 Tests are also available which use purified antigens mainly 38kDa and 
30kDa. The former is very specific and the latter is highly immunogenic and 
more sensitive. Antibody detection by enzyme linked immune-sorbent assay 
(ELISA) or other serological tests are of limited use since less than 70% of 
patients produce specific antibody in high levels. Moreover, presence of 
antibody does not indicate current disease or past infection. Accordingly, 
presence of antigen may be a better indicator of the disease than the antibody. 
 However, antigen quantity in circulation is usually very limited and 
masked by the antibody and hence difficulty to detect. Though various tests 
have been attempted, there is none that can be recommended and is widely 
used. 
 A recent WHO study found that TB rapid diagnostic tests currently 
available in the market vary widely in performance, with some products 
showing a high lot-to-lot and reader-to-reader variability. At less than80%, 
the specificity was poor in the majority of products when tested in TB 
suspected cases from endemic settings. Those tests with a better specificity 
(over 90%) had poor sensitivity, detecting fewer than 40% of TB patients. 
The tests performed even worse in HIV co-infection samples the conclusion 
of a review of several studies showed that none of the assays perform well 
enough even to replace microscopy. 
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ANTIGEN DETECTION TEST 
Lipoarabinomannan Urine Test 
 The tests detect lipoarabinomannan (LAM) in urine as a surrogate 
marker for mycobacterium tuberculosis infection. 
 Lipoarabinomannam is a component of the TB bacterial cell wall. The 
test exists in ELISA and simplified “tube” format. Clinical trials to develop a 
dipstick format are ongoing. The simplified tube format is apparently robust 
and does not require cold chain. 
Flow – Through Filter Tests 
 These tests rely on detection of mycobacterium tuberculosis in sputum 
or body fluids with a polyclonal antibody, using a flow-through device. 
NUCELIC ACID AMPLIFICATION TESTS 
Nucleic Acid Probes 
 Deoxyribonucleic acid (DNA) hybridization technique detects small 
numbers of mycobacterium tuberculosis with no cross hybridization with non-
mycobacterial respiratory pathogenswith sensitivity equivalent to smear 
examination by Z-N staining. 
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POLYMERASE CHAIN REACTION 
 Polymerase chain reaction (PCR)is extremely sensitive and 
specifictechnique
32
. A protocol for detection of insertion element IS6110 was 
described and it gave a positive result in nine out of the fifteen TB pleural 
effusions, while a PCR for conserved region was positive in only three of 
these patients. 
 However, it was also reported that when different specimens from the 
same patient were tested, positive results were obtained intermittently 
33
. 
 Initially developed PCR could detect as low as 10 bacilli in the 
specimen. Recent modifications have enabled DNA extracted from a fraction 
of a bacilli to be detected after suitable amplification. 
 The DNA ligase functions to link two stands of DNA together to 
continue a double strand segment. The seal can reliable take place only if the 
ends are complementary and are an exact match. In ligase chain reaction 
(LCR), the fragmented primers are four in number and are added in excess. 
Results from PCR and LCR tests are available in three days as compared to 
culture which takes six weeks. Its power can, however, be its greatest 
weakness as even the smallest amount of contaminating DNA can be 
amplified, resulting in misleading results. 
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AMPLIFIED MYCOBACTRIUM TUBERCULOSIS DIRECT TEST 
 Amplified mycobacterium tuberculosis direct test is specific test for 
mycobacterium tuberculosis complex. It is an isothermal transcription 
mediated amplification (TMA) test in which the target is the mycobacterial 
16SrRNA.the entire process is performed at 42 degree C. 
 The test is highly specific, and gives result within three hours. This is 
the first test to be approved by the FDA for smear positive respiratory 
specimens. Similarly, other PCR test systems that target 16SrRNA including 
the real time assays have been developed. 
 Efforts are being made to simplify the nucleic acid testing systems. In 
loop mediated isothermal amplification (LAMP), mycobacterium tuberculosis 
DNA is amplified directly from clinical samples. A positive result in signalled 
by a colour reaction visible to the naked eye. 
 Overall, sensitivity of nucleic acid amplification tests (NAAT) is 
higher when test is applied to the respiratory sample as opposed to other body 
fluids 
34
. 
Geno Type Assays 
 Two geno type assays are commercially available. The first is for TB 
diagnosis(Geno type myco bacteria assay), the second for detection of 
rifampician and isoniazid resistance (geno type MTBDRassay). 
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 Isolation is commonly done by PCR amplification of the 16S-23S 
ribosomal DNA spacer region followed by hybridization of the biotinylated 
amplified DNA products with 16 specific oligonucleotide probes. The specific 
probes are immobilized as parallel lines on a membrane strip. 
Polymerase Chain Reaction Sequencing 
 Specific mycobacterium tuberculosis genetic material is amplified and 
sequenced, allowing the DNA to be “read”. This is a gold standard and most 
widely used method for defining genetic resistance for drug sensitivity 
testing. It has been commonly used for characterising mutations in the rpoB 
gene in rifampicin resistant strains and to detect mutations responsible for 
other antituberculosis drugs. 
Drug Susceptibility Testing 
 The DST tests should be performed in the following instances: (I) for 
relapse or treatment cases; (ii) To change the drug regimens when drug 
resistance is suspected; and (iii)undertaking drug resistance surveillance 
studies in a region/country. 
 Direct method 
 Indirect test 
1. Absolute concentration method 
2. Resistance ratio method 
3. proportion method  
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  Microscopic-observation drug-susceptibility assay(MODS). 
BIOLOGICAL AND IMMUNOLOGICAL MARKERS 
 Adenosine deaminase and interferongamma. 
DIAGNOSIS OF MDR TB 
CONVENTIONAL METHODS 
 Traditionally Lowenstein Jenson(LJ) culture has been used for drug 
sensitivity testing using i) absolute concentration method ii) resistance ratio 
method iii) proportions method .In resistance ratio method MIC of isolated is 
expressed as multiple of MIC of standard susceptible strains.  
 In proportion method ratio of number of colonies growing on drug 
content medium to number of colonies in drug free medium is compared. 
Modern methods 
 Radiometric methods have been developed for rapid drug susceptibility 
testing of M. Tuberculosis.  In the BATEC-46(Becton Dickinson THIZ 
medium contains palimitic acid labelled with radioactive (C14 palimitic acid) 
detects radioactive carbon dioxide as mycobacterium metabolise these fatty 
acid 
23,24
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 The mycobacterium growth indicator tube is rapid non-radioactive 
method oxygen sensitive compound restriction fragments length 
polymorphism has facilitated elucidation of molecular epidemiology  of TB. 
LCR (ligase chain reaction) involves the use of DNA ligase, Luciferase 
reporter assay is a moral reporter gene assay system fast plaque TB-RIF a 
rapid detection   tests Genetic mechanism. 
 The line probe assay(lipA;INNO genetic NA) has been based on  
reverse hybridisation method consist of PCR amplitude of segment of rpo B 
genetic followed by denaturisation and hybridisation of bio tiny  PCR amp 
icons to capture probes bound to micro cellulose strip. 
 The emergence of MDR-TB is a threat for population of resource 
limited countries, low socio economic states  of the people, high prevalence of 
infectious diseases and cases to well-equipped health care facilities worsens 
the effect of MDR-TB further more poor treatment outcomes, longer 
treatment higher treatment cost and many more complication  makes MDR-
TB complex diseases. 
Prevalence of MDR TB in cat II TB patient was high and these patients 
are at high risk of amplified resistant, in this view of high risk of MDR-TB 
among cat II retreatment. 
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This study was carried out to compare the various factors among the 
drug susceptible in the drug resistant and compare the factors which might to 
contribute towards the development of multi drug resistant tuberculosis, 
which may help identify various risk factor for development of MDR-TB, 
helps in the treatment of drug susceptible and drug resistance case 
MDR Worldwide 
 Though studies published from the developing world suggested that 
drug resistance was a potential problem
35
 it was emergence of MDR-TB on 
USA in 1990 attracted  the global extent of problem of drug resistant  
tuberculosis is evident on the report by WHO International Union agent 
Tuberculosis and long disease (IUATLD) global prefect on anti-tuberculosis 
drug resistant surveillance between 1994 and 1997. 
 In this study drugresistantce was found to be prevalent in 35 countries 
suggesting it to be global problem therefore WHO – UATLD 36,37 survey was 
extended to define the problem further between 1996 and 1999 patient and 58 
countries surveyedfor newly diagnosed patients,  frequency of resistance to, at 
least one anti-tuberculosis drug ranged from 1.7% in urguay to 36.9 in 
Estonia, china(10.8%), Russian oblast of Ivano(9%), Results of resistance 
survey from 64 countries together with data predicted of 72 others suggested, 
new cases of MDR TB occurred worldwide constituted 3.2% of all new cases.  
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 Isoniazid the most powerful mycobactecidal drug available ensures 
early sputum conversions and helps in decreasing the transmission of TB. 
Rifampicin by its mycobactericidal and sterilizing activities is crucial for 
preventing relapse thus isoniazid and rifampicin are keystone drugs in 
management of TB. While resistance to either isoniazid and rifampicin may 
be managed with other first IM-drugs resistance to both isoniazid and 
rifampicim is MDR-TB demands treatment with second line drugs. 
 These drugs have limited sterilizing capacity and are not suitable for 
short course chemotherapy thus patient with MDR-TB required prolong 
treatment, in less effective and more toxic drugs. 
 Primary resistance is that which has not resolved from the treatment of 
the patient with the drugs concerned. It included resistance in wild strains 
which have never came in contact with the drugs (natural resistance) and the 
resistance occurring as result of exposure of the strain to the drug but in 
another patient.  Initial resistance is the resistance in patient who give a 
history of never having chemotherapy of includes both primary resistance and 
resistance by previous treatment concerned by patient 
38
. 
 The terms acquired resistance has often been used with implications 
that resistance has developed due to exposure of strain to anti-tuberculosis 
drugs and consequent selecting out of resistant mutant bacilli. 
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However some of drug some of drug resistant isolated in previously 
treated patient may actually represent primary resistance among patient who 
remains incurred if initial drug susceptibility testing has not been done
39
. The 
term resistance among previously treated patient would be a more 
approximate term than acquired drug resistance
40
susceptible strains are those 
that have not been exposed to main anti-tuberculosis drugs and respond to this 
drugs in a uniform manner. 
Resistant strains differ from the sensitive strain in their capacity to 
grow in presence of higher concentration of drug. Wild strains are those that 
have never been exposed to drug naturally resistant strains are wild strains 
resistant to drug without having a contact to it. 
 Various factors have been implicated in the  
CAUSATION OF MDR-TB 
1. Genetic factors 
 Though there is some evidence to postulate host genetic predisposition 
as the basis for the developments of MDR-TB, it has conclusion 
41, 42
. In a 
recent study from India patient with HLADRB113 and DRBI 14 were found 
to have two fold increases risk of developing MDR-TB. Partly 84-34 found 
that susceptibility history of MDR-TB in Korean patient was strongly 
associated with HLA DRBI 08032-DQBI 0601 haplotype. 
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 The exact role of the factors is not known. It is likely that these loci or 
alleles linked with then play a permissive role of  increasing susceptibility to 
development of MDR-TB. 
FACTORS RELATED TO PREVIOUS ANTI-TUBERCULOSIS  
TREATMENT 
 Incomplete and inadequate treatment, review of published literature 
strongly suggested that the most powerful predictor of the presence of MDR-
TB is the history of treatment of tuberculosis. 
 TB patient in India get treated with DOTS regimens, not only theory of 
Revised National Tuberculosis Control Programme (RNTCP) but also receive 
treatment from private medical practitioners, irregular treatment is 
commonest mean of acquired drug resistant organism
43
.   
 Mahumoudi and Isman.et al
44
 observed that among the 35 patients with 
MDR patients errors in management decision occurred in 28 patients, at an 
average of 3.93 errors per patients. The most common error is addition of 
single drug to  regimen, failure to identify persisting or acquired drug 
resistance, initiation of an adequate primary regimen when the patient appear 
to be detoriate clinically. 
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Inadequate treatment complaints 
 Poor compliance with treatment is also an important factor in the 
development of acquired resistance. In a study conducted in South India
45
45% 
of patients receive short course (n-2306) and 35% of those receiving standard 
chemotherapy (n+1051) completed 80 percent of treatment, non- compliance 
with  prescribed treatment is often underestimated by the physician and is 
difficult to predict. 
 The drug defaulter, just like placebo reactor is not a consistent or 
readily identified person 
46
. In west demographic factors given as age, sex, 
marital status, socio economic status have been not found to like degree of 
compliance on the one hand certain factors such as psychiatric illness, 
alcoholism, drug addiction and homelessness do predict non-compliance. 
 This may not be entirely true in Indian context and the relevance of 
these factors in Indian scenario merits the further study.
47
Santha etal.studied 
the risk factors associated with default,failure death among TB patients 
treated in TB patients, In this study in multivariate analysis higher default 
rates were associated with irregular treatment, male sex, history of previous 
treatment, alcoholism. Higher death rates were independently associated with 
weight less than 35kg. 
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 Jhonson et al
48
 found high incidence of drug resistance in previous 
treatment defaulters. The various reason for default included travel to 
different places, symptom relief, adverse drug reaction and inability to effort 
treatment, Good reliable laboratory support is not accessible in developing 
nations. Unfortunately these are the areas where MDR-TB is major health 
hazard.  
 This program of tuberculosis control was assessed in a sputum positive 
tuberculosis. Drug resistance data on admission were available for 131 patient 
and 55 percent of patients had of mycobacterium tuberculosis resistant to one 
or more drugs mortality drug treatment was 11 percent and 13 percent 
treatment was successful in 54 percent of patient, in 71 percent of treatment 
completing patients. Similar observations were made in another study with 
results of treatment with first line drugs enrolled with WHO and IUALTDS 
global project on drug resistance surveillance. 
 This data suggest that short course chemotherapy based on first line 
drugs  inadequate for some patients with drug resistant TB
49
. Although DOTS 
strategy is basis of good control of TB, the strategy should be modified in 
some settings to identify drug resistant cases source and to make use of 
second line drugs in approximate treatment. 
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PREDICTORS FOR DEVELOPMENT OF MDR-TB 
 Certain factors have been documented to associated with development 
of MDR-TB. In a analysis to identify determinants of drug resistance, 
population based  data a, new and previously treated patient with TB collected 
within an international drug surveillance networks were studied 
50
. 
 Of the 9,615 patient 85.5% were new cases compared with old cases, 
patients who received treatment in the past were more likely to have 
resistance to anti-tuberculosis drugs. Multivariate analysis revoked that prior 
anti-tuberculosis treatment but not HIV positivity.In Saudi Arabia previous 
history of anti-tuberculosis treatment young age were found to risk factors. 
 In a study from
51
henan province, past history of tuberculosis, poor 
compliance to treatment, low socio economic status and body mass under 
contributors to risk of developing MDR-TB. In most of published study 
previous history of the tuberculosis and past history of anti-tuberculosis 
treatment have been implicated in the cause of MDR-TB.  Parketal  reported 
that extra pulmonary involvement was risk factor for shorter survival while a 
cavitation lesions on initial chest film treatment was high risk factor. 
Predictor’s survival in patient MDR-TB 
 DOTS is key in the tuberculosis control strategy. In population where 
MDR-TB is endemic the outcome of short course regimen 
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uncertain.unacceptable Failure rates  have been reported and resistance to 
additional agent may induced
51
. 
 As a consequence there has been cause for well factor of DOTS 
programme to provide addition service. The WHO has also established 
greenlight committee in attempt to promote access to and rational use of 
second give anti-tuberculosis drugs and treatment of MDR-TB 
52
. 
Nutritional enhancement 
 Tuberculosis is a wasting disease, the degree of cachexia is most 
profound where MDR-TB occurs in patient with HIV co-infecteion; while the 
mechanism involved in weight loss are not well known, current evidence 
points to tumour (TNF-alpha) to be the cytokines responsible for 
phenomenon. 
 Though definitive evidence is not yet available it is generally believed 
that malnourished patients are as greater risk of developing post-operative 
complications
53
. Nutritional assessment and regular monitoring of nutritional 
state by a discussion are essential for the successful management of MDR-TB 
Patients. 
 There are limited data‟s are available on the risk factors for multidrug 
resistant tuberculosis. Various factors that might contribute towards the 
development of multidrug resistant tuberculosis was analysed in various 
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studies all over the world.  Larger studies showed involvement age, gender, 
education, economy, defaulter, alcoholism towards the development of MDR 
TB.  Age distribution pattern in many study showed peak levels of defaulting 
are in the >45 year 
54
. 
 In another study in ODISHA
55
 towards factors for sourceful outcome 
in pulmonary tuberculosis showed factors such as young age, high income, 
high education, regular treatment favours  for  the positive outcome of 
disease. Determinate of MDR TB published in IRS annul congress 2012 
showed a positive correlation of MDR TB with previous treatment. 
 Similar study in eastern, Ethiopia analysed risk factors for un-
successful tuberculosis treatment outcome
56
 showed association  unsuccessful 
treatment with age, previous history of treatment, HIV-TB co-infection. 
In other study
57
 done in kuwait towards determinants of defaulter and 
MDR TB suggested association of history of defaulter Low education, male 
sex, homelessness, smoking, Alcohol, drug based towards development of 
MDR TB.  
 In case control study of diabetes and other risk Factor for multi drug 
resistant tuberculosis in a Mexican population
58
. The important finding in this 
study was Association between diabetes and MDR TB (47.2%). In onestudy 
by Gimenez et al  DM associated with a Higher frequency of cavities among 
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diabetics possible explanation for the increased frequency of MDR-TB among 
DM-TB Patients include a) to maintaince phase of anti-TB treatment   
b) higher mycobacterial  burden in DM-TB patients. 
 Results from national survey of south Africa
59
 for the determinate of  
multi drug resistant TB patients showed resistance cases were consistenly 
high in previous treated cases, the role of HIV as an independent risk factor 
for MDR remains inconculsive. A case control study by addis abba
60
showed 
high prevalence  of MDR among retreatment cases, male, smoker, alcohol. 
The study also showed important finding very low association of HIV 
towards the development MDR TB.  Thailand study also showed insignificant 
association of HIV with MDR
61
. 
 In France being HIV positive was associated with primary MDR TB 
but it was not associated with secondary MDR TB 
62
. Risk factor of multi 
drug resistant in urban Allahabad
63
 again confirmed association of MDR TB  
with males, previously treated cases substance abuse, and with associated co-
morbidities, in controversy to other  studies it showed association of MDR  
with young age. 
 Similar study from henan province case control study 
64
 compared the 
various factor involved with development MDR TB assured the association  
of previous treatment, male sex, low education, unemployment, smoking, lack 
of awareness towards the development with significant (C OR 95%,P value). 
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The study also recommended associations of HIV-TB co-infections for the 
association factors associated with treatment defaulter by tuberculosis patient 
in morocco showed smoker, alcoholic associated with development of MDR 
Or(95% CI). 
Relapsed case   4.49 (1.87 -10.1) <.001       
Chronic smoker 2.10 (1.07 -4.14) 0.03 
Alcohol user   2.92 (1.04 -8.19) 0.04 
 Risk
65
 factors for multidrug resistant TB showed once again 
association of prior treatment, economy, illiterate. This study significantly 
associated HIV towards the development of MDR in contrary to other studies. 
Variables COR (95%CI) ADR (95%) P-value  
History of Previous 
Treatment 
   
Yes 20.5 21 0.001 
No 1.00 1.00  
Infected with HIV    
Yes 2.46 
(1.33-4.55) 
3.1 0.46 
No 1.00 1.00  
 
 Another
66
Study showed prevalence of MDR among category II patient 
was about 20.4 % tuberculosis among HIV patient in India was3-5% in new 
cases 15-20% in retreatment cases) which was again showed in various study 
in India withabove background we carriedout our study to determine 
predisposing factor forMDR TB. 
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AIM OF STUDY 
 To  Compare the predisposingFactors towards the developmentof drug 
susceptible anddrug resistance pulmonary TBre-treatment cases. To analyse 
the factors which might contribute the development multidrug resistant 
tuberculosis. 
OBJECTIVES 
 To determine factors leading to development multidrug resistant 
tuberculosis. 
 
 
 
 
 
 
 
66 
 
METHODLOGY 
1. Title of the study : Comparison of predisposingFactors 
towards the developmentof drug 
susceptible and drug resistance 
pulmonaryTBre-treatment cases. 
2. Site of Investigation : GHTM  
3. Principal Investigator  
a) Name   : Dr. G.K.BALAJI 
b) Qualification  : M.B.B.S M.D(Post graduate in T.B & RD) 
c)  Institution  : Govt. Stanley Medical College Hospital 
4. Co-investigators     : Dr. SRIDHAR (MD CHEST,DTRD) 
a) Name   : Dr. VINODKUMAR (MD CHEST,DNB) 
   Dr. NANCY GLORY( MD CHEST) 
   Dr. VENKADAKRISHNARAJ(DTCD, 
   DNB(CHEST) 
   Dr. MAHESWERAN (M.D CHEST). 
5. Aim/Goal of the study : To evaluate the factors contributing 
   to development MDR TB  
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6. Primary Objectives      : To compare and analyses various risk 
factors associatedwith pulmonary TB 
defaulters towards development of  MDR 
TB 
7. Secondary Objectives  : Identifying the risk factors and avoiding it. 
To prevent  development of MDR TB. 
8. Hypothesis/Research  
question   : What are the risk factor towards   
     developmentMDR TB        
9. Study design  : Type of study -prospective   
10. Work plan /Timeline : Approx time for sample collection –10 
months Study data analysis  one month.  
11. Ethical Clearance  : The various investigations and procedures 
that will be used in this study will be as per 
protocol. The identity of each patient will 
be kept confidential. This study will not 
violate medical ethics in anyway 
12. Study population : Pulmonary TB retreatment casesand MDR 
  patientsin GHTM 
14. Inclusion criteria : 1) All patients with pulmonary  
     TB retreatment and MDR cases. 
2) Age > 15 years 
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14. Exclusion criteria            : 1) Patients with only extrapulmonary TB 
   2) Age < 15 years 
   3)  Patients who are moribund, sick  
   and unableto produce sputum. 
4)  Patients who are not willing  
to participate in the study                                                                                               
15. Collection of clinical  
samples/data : Specify type  
                                                       1. Recruitment  as perInclusioncriteria  
2. Symptom diagnosis  
3. Chest  radiograph 
4. Sputum AFB smear 
5.CB-NAAT result 
6. Culture results 
16. Methodology     : Technique  
     Sample size-100 
     Source of the study population –GHTM  
     Study design-Prospective. 
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To find the relationship between commonly associated risk factor such 
as: 
1. Age<15, 15-45,>45 
2. Gender 
3. Education-illiterate , literate 
4. Economic status  
           -   3000/month 
           -> 3000/month         
5. History of contact with MDR 
6. HIV status 
7. Diabetic status  
8. Alcohol consumption, smoking, cavitation in chest x-ray 
9. Category of treatment  
 - defaulter 
- treatment failure 
- relapse 
- new case 
10.  Treatment history : 
 Towards the development of MDRTB among TB retreatment cases 
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11. Laboratory investigations: Chest  Xray, Sputum Smearfor AFB,DST
     Tridot for HIV,CD4 count, FBS, PPBS, 
     LPA. 
12. Statistical analysis  :  As per standard statistical method. 
 
13. Involvement of other  
centres   : NIL 
14. Requirement of Funds   : NIL 
15. Conflict of interest if any: NIL 
16. Significance of the study: Identifying the risk factors associated 
     withDevelopment of MDR helps to  
     prevent the MDR TB. 
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RESULTS AND OBSERVATION 
COMPARISON OF DRUG SENSITIVE AND DRUG RESISTANT 
PULMONARY TUBERCULOSIS RETREATMENT CASES 
Results 
Descriptive statistics 
 Among Defaulter, frequency of default,  
Inferential statistics 
 Association of frequency of default and resistance 
COMPARISON OF DRUG SENSITIVE AND DRUG 
RESISTANTPULMONARY TUBERCULOSIS RETREATMENT CASE 
TOWARDS DEVELOPMENT OF MDR 
S.No. Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. 
Age 
Group 
>45 
years 
102 68% 78 52% 
< 45 
years 
48 32% 72 48% 
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Descriptive statistics 
Result: 
Charts / Figures 
Comparison of frequency distribution of age in two groups. 
 
Inferential statistics 
S.No. Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
1. 
Age 
Group 
> 45 
years 
78 48 
0.00 
2.29  
(1.43 – 3.68) 
   
< 45 
years 
72 102 
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Sex distribution 
Drug resistant group 
Drug sensitive group  
S.No. Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
2. Sex 
Male 104 69.3% 114 76% 
Female 46 30.7% 36 24% 
 
 
S.No. Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
1. Sex 
Male 104 84 
0.01 
1.77  
(1.10 – 2.86) 
Female 46 66 
 
 
76%
Female
24%
Drug sensitive
70%
Female
31%
Drug resistant
74 
 
Inferential statistics 
S.No
. 
Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequenc
y 
Proportio
n 
Frequenc
y 
Proportio
n 
3. 
Educatio
n 
Illiterat
e 
82 54.6% 48 32% 
Literate 68 45.3% 102 68% 
 
Descriptive statistics 
Results 
 
S.No. Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
1. Education 
Illiterate 82 48 
0.00 
2.55  
(1.59 – 4.1) Literate 68 102 
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Inferential statistics 
S.No. Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. Economy 
<3000 94 62.6% 48 32% 
>3000 56 37.3% 102 68% 
 
 
Descriptive statistics 
Results 
S.N
o. 
Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
1. Economy <3000 94 48 0.00 2.55  
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>3000 56 102 
(1.59 – 4.1) 
 
S.No. Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. 
Treatment 
History 
New case 6 4% 0 0% 
Defaulter 91 60.6% 111 74% 
Relapse 41 27.3% 34 22.6% 
Treatment 
failure 
12 8% 5 3.3% 
 
 
S.No. Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P 
value 
Odds ratio 
with 
confidence 
limits 
1. 
Treatment 
History 
New case 6 0 
0.009  
Defaulter 91 111 
74
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Relapse 41 34 
Treatment 
failure 
12 5 
 
S.No. Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. 
Diabetes 
history 
+ 48 32% 32 21.3% 
- 102 68% 118 78.6% 
 
Inferential statistics 
Descriptive statistics 
Results 
 
S.
No. 
Variable 
Drug 
resistant 
group 
Drug 
sensitive 
group 
Chi 
square 
test 
Odds ratio 
with 
confidence 
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(n=150) (n=150) P value limits 
1. 
Diabetes 
history 
+ 48 32 
0.03 
1.73  
(1.03 – 2.93) 
- 102 118 
 
S.No
. 
Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. 
HIV 
status 
+ 8 5.3% 7 4.6% 
- 142 94.7% 143 95.3% 
 
 
Inferential statistics 
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S.No. Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
1. 
HIV 
status 
+ 8 7 
0.01 8.39 
- 142 143 
 
Descriptive statistics 
Results 
S.No. Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. 
Alcohol 
history 
+ 76 50.6% 42 28% 
- 74 49.4% 108 72% 
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S.No. Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
1. 
Alcohol 
history 
+ 76 42 
0.00 
2.6  
(1.6 – 4.2) 
- 74 108 
 
Inferential statistics 
S.N
o. 
Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. 
Smoking 
history 
+ 40 26.6% 25 16.6% 
- 110 73.3% 125 83.3% 
 
Descriptive statistics 
Results 
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S.No. Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
9. 
Smoking 
history 
+ 40 25 
0.03 
1.8  
(1.0 – 3.2) - 110 125 
S.No. Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. Cavitation 
+ 43 28.6% 23 15.3% 
- 107 71.3% 127 84.6% 
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Inferential statistics 
S.No
. 
Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi 
square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
1. Cavitation 
+ 43 23 
0.00 
2.21 
(1.25 – 3.95) 
- 107 127 
 
COMPARISON OF DRUG SENSITIVE AND DRUG RESISTANT 
PULMONARY TUBERCULOSIS RETREATMENT CASE TOWARDS 
DEVELOPMENT OF MDR 
Results 
Descriptive statistics 
S.No. Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
Frequency Proportion Frequency Proportion 
1. Age > 45 years 102 68% 78 52% 
43
23
107
127
0
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40
60
80
100
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140
160
Drud resistant Drug sensitive
F
r
e
q
u
e
n
c
y
Cavitation and sensitivity pattern
Cavitation + Cavitation -
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Group < 45 years 48 32% 72 48% 
2. Sex 
Male 104 69.3% 114 76% 
Female 46 30.7% 36 24% 
3. Education 
Illiterate 82 54.6% 48 32% 
Literate 68 45.3% 102 68% 
4. 
Treatment 
History 
New case 6 4% 0 0% 
Defaulter 91 60.6% 111 74% 
Relapse 41 27.3% 34 22.6% 
Treatment 
failure 
12 8% 5 3.3% 
5. 
Diabetes 
history 
+ 48 32% 32 21.3% 
- 102 68% 118 78.6% 
6. 
HIV 
status 
+ 8 5.3% 7 4.6% 
- 142 94.7% 149 99.3% 
7. 
Alcohol 
history 
+ 76 50.6% 42 28% 
- 74 49.4% 108 72% 
8. 
Smoking 
history 
+ 40 26.6% 25 16.6% 
- 110 73.3% 125 83.3% 
9. Cavitation 
+ 43 28.6% 23 15.3% 
- 107 71.3% 127 84.6% 
 
 
 
Among Defaulter, frequency of default  
S.N Variable 
Drug resistant group 
(n=150) 
Drug sensitive group 
(n=150) 
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o. Frequency Proportion Frequency Proportion 
1. 
Defaulter 
frequency 
>1 74 82.2% 28 25.2% 
< 1 17 18.8% 83 74.7% 
 
 
 
Association of frequency of default and resistance 
S.N
o. 
Variable 
Drug 
resistant 
group 
(n=91) 
Drug 
sensitive 
group 
(n=111) 
Chi 
square test 
P value 
Odds ratio 
with 
confidence 
limits 
1. 
Defaulter 
frequency 
>1 74 28 
0.00 
12.7  
(6.5 – 25.6) < 1 17 83 
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Inferential statistics 
S.No. Variable 
Drug 
resistant 
group 
(n=150) 
Drug 
sensitive 
group 
(n=150) 
Chi square 
test 
P value 
Odds ratio 
with 
confidence 
limits 
1. Age Group 
> 45 years 102 78 
0.00 
2.29 
 (1.43 – 3.68) < 45 years 48 72 
2. Sex 
Male 104 84 
0.01 
1.77  
(1.10 – 2.86) Female 46 66 
3. Education 
Illiterate 82 48 
0.00 
2.55  
(1.59 – 4.1) Literate 68 102 
4. 
Treatment 
History 
New case 6 0 
0.009  
Defaulter 91 111 
Relapse 41 34 
Treatment 
failure 
12 5 
5. 
Diabetes 
history 
+ 48 32 
0.03 
1.73  
(1.03 – 2.93) - 102 118 
6. HIV status 
+ 8 7 
0.01 8.39 
- 142 143 
7. 
Alcohol 
history 
+ 76 42 
0.00 
2.6  
(1.6 – 4.2) - 74 108 
8. 
Smoking 
history 
+ 40 25 
0.03 
1.8  
(1.0 – 3.2) - 110 125 
9. Cavitation 
+ 43 23 
0.00 
2.21  
(1.25 – 3.95) - 107 127 
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DISCUSSION 
In our study we found factors which are  predominant in drug resistant 
pul.TB cases,Which are evidenced by so many previous studies as discussed 
earlier, statistical analysis and percentage of patients among the drug resistant 
and drug susceptible retreatment cases show team association of these factors 
towards development of drug resistant Tuberculosis. 
 Drug resistant pul.TB patients  were predominantly >45 years about 
68% ,among drug susceptible pul.TB patient were years 52%.descriptive 
statistical analysis show with p value of 0.00 and CL of (2.29). 
Drug susceptible and drug resistant pul.TB retreatment cases has the 
male predominant ,which can been seen as about 69.3%&76%, which shows 
predominant of drug susceptible and drug resistant TB among males which 
can be attributed to various coexistent factors like alcohol, smoking, 
occupational history which leads increased defaults among the male patient 
which again leads to development of MDR TB. 
In a similar fashion we found that literate person among drug resistant TB  
patients around 45.3% while illiterate around 54.6%, majority of literate 
patient were seen in drug sensitive patient which again reveals literacy and 
awareness about treatment of pulmonary TB has causal relationship with 
development of MDR TB. 
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Economy of  patient does have role among causation of drug resistant 
pulmonary TB patient, Although patient with poor income can be seen 
predominately on both drug susceptible  and drug resistant cases. Most of 
drug resistant pulmonary TB patients 72% were seen with very low income 
which might attribute to increase in frequency of default. 
The most important factor in our study we observed is that strong 
association of frequency of default among drug resistant cases. Most of 
retreatment cases who had less frequency of default fell into category of Drug 
susceptible retreatment cases, while those frequency of default more than 2 
times were predominantly seen among drug resistant pul.TB  
 Defaulter >2 were 60.6%  among drug resistant patient, most of patient 
had defaulter frequency greater than 2, while drug sensitive most of patient 
had decreased frequency of default when compared to drug susceptible 
retreatment cases. 
Similarly we observed  marginal  increase in  drug resistant cases 
among diabetes mellitus 32%, while drug sensitive were about 21.3% 
inferential statics showed that  diabetes mellitus might contribute to 
development of drug resistant cases with p value of 0.03 with OR (cl) 1.73 
(1.02-2.93). 
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Interesting observation we had was very low frequency of HIV patients 
among drug resistant pulmonary TB retreatment cases, which favours toward 
lesser degree of association of HIV towards development of drug resistant 
cases. 
Association of alcohol and smoking had significant role towards 
development of drug resistant retreatment cases. Although in our study we 
had almost equal number of non alcoholic (49.4%) and alcoholic (50.6%) as 
drug resistant cases. Most of non alcoholic were drug sensitive retreatment 
case whohad decreased frequency of default which strongly favors towards 
the development of drug resistant cases, similar observation were also made 
among smokers. 
As so many previous study revealed, we also found to have increased 
frequency of drug resistant retreatment cases with cavities  in the chest x-ray 
predominance of patient with lung cavities  in cxr was suggestive of 
association of lung cavities  towards development of drug resistant cases 
which can be explained poor penetration of drug in the cavities increased 
loads of bacilli in cavities  . 
In our study we observed increased proportion  drug resistant cases 
were  seen in group > 45 yrs, male, illiterate, with poor income. Most of them 
were smoker, alcoholic, we also observed predominance of diabetes, lung 
cavities  incxr  among drug resistant cases. Most of drug resistant cases had 
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strong predisposition towards frequency of default of pulmonary TB 
treatment. As frequency of default increases, we found increase multidrug 
resistant TB. Persons with HIV-TB remained same both groups. 
CONCULSION 
In our study comparing the drug susceptible and drug resistant pul.TB 
re-treatment cases. We found factors like Age >45, male, TB treatment 
defaulter > 1 times, diabetes milletus, alcohol and smoking,dominates in drug 
resistant re-treatment cases. Early identification persons with this risk factor, 
giving extra care and follow up can reduce prevalence of MDR which is about 
20.3%in re-treatment cases. 
 Special care, nutrition, health workers follow up, for these person at 
risk will definitely help in controlling multidrug resistant TB and its 
economic, social burden. 
Alcoholic de-addiction centre along with sanatorium type of care for 
these patients with risk factors, can definitely reduce multi drug resistant 
tuberculosis, can help the humanity towards pathway of END TB strategy. 
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ANNEXURES 
PROFORMA 
1. Age     : 18-25 yrs 
      25-45 yrs 
      >45 yrs 
2.Sex     : Male 
      Female 
3.Education    : Illiterate  
      Literate 
4.Montly income                          :   <3000/month 
      >3000/month  
5.Smoking                                    :  Smoker- No. of Cigarettes/ Day 
      Non-smoker 
6.Alcoholic consumption             :  Yes 
      No 
7.HIV status    : Negative 
      Positive 
8.Diabetic status   : Non-diabetic 
      Diabetic-controlled, uncontrolled. 
9.a)Treatment history  : Previously untreated 
      Treated 
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b)Number of previous  
treatment    : 0-2 
      2 and above 
c)Category of treatment        : Defaulter 
      Treatment failure 
      Relapse 
      New case  
d)Irregular treatment    : Intensive phase 
      Continuous phase  
10.History contact with MDR : 
11.Cavitations of cxr                   : Yes 
      No 
12.Other co-morbidities            :  Hypertension 
IHD 
Kidney disease 
Liver disease 
13.Others if any   : 
14.Investigation                           : Sputum smear for AFB 
      Cxr 
      Tridot for HIV,CD4 
      LPA  
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CONSENT FORM 
 I Mr / Mrs / Miss / ____________________________ have understood 
the procedure read by the Doctors. I in my whole conscious awareness give 
consent for the procedure. I understand that the procedure is done in good 
faith for the best therapeutic results possible. I fully understand the 
consequences of the procedure. I can resign from the study at any point of 
time.  
 
Signature   
 
Name               :   
Date and Time     :  
Signature of Researcher   :  
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_¯ J¨¦uÀ £iÁ® 
 
 
Bµõ´a] |ø»¯®   : Aµ_  ö{g\P ÷{õ´ ©¸zxÁ©øÚ  
     uõ®£µ® \õÚ÷hõ¶¯®, ö\ßøÚ. 
 
£[S ö£Ö£Áº ö£¯º  :  
 
£[S ö£Ö£Áº Gs.  : 
 
£[S ö£Ö£Áº (      ) CuøÚUSÔUPÄ® 
 
 
 ÷©÷» SÔ¨¤h£mkÒÍ B´Âß ÂÁµ[PÒ GÚUS ÂÍUP¨£mhx. 
 GßÝøh¯ \¢÷uP[PøÍ ÷PmPÄ®, AuØPõÚ uS¢u ÂÍUPøÍ¨ ö£ÓÄ® 
Áõ´¨£ÎUP¨£mhx. {õß C¢u B´ÂÀ ußÛaø\¯õPzuõß £[÷PØQ÷Óß. G¢u 
PõµnzvÚõ÷» G¢u Pmhzv¾® G¢u \mh ]UP¾US® Em£hõ©À Â»QU 
öPõÒÍ»õ® GßÖ AÔ¢x öPõs÷hß. 
 C¢u B´Ä -»® QøhUS® uPÁÀPøÍ²® £¶÷\õuøÚ ¬iÄPøÍ²® ©ØÖ® 
]Qaø\ öuõhº£õÚ uPÁÀPøÍ²® ©¸zxÁº £¯ß£kzv öPõÒÍ \®©vUQ÷Óß. 
  
102 
 
 
÷{õ¯õÎUPõÚ uPÁÀ £iÁ® 
 
©v¨¤ØS¶¯ I¯õ, 
 E[PÒ Â¸¨£vß ÷£¶À C¢u B´ÂÀ £[S÷PØS®£i  Aß¦hß ÷PmkU 
öPõÒQ÷Óõ®. C¢u B´ÂÀ Bµõ´a] ÷{õUPzxUPõP uõ[PÒ £¶÷\õuøÚUS 
Em£kzu £kÃºPÒ uS¢u ]Qaø\ u[PÐUS öuõh[P¨£k®. C¢u B´ÂÀ £[÷PØP 
Â¸¨£® C¸¢uõÀ J¨¦uÀ £iÁzøu £izx¨£õºzxU øPö¯õ¨£® Ck®£iU 
÷PmköPõÒQ÷Óß. 
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 MASTER CHART 
 
DRUG RESISTANT 
 
SL. 
NO. 
NAME AGE SEX EDUCATION 
NEW 
CASE 
TREATMENT HISTORY 
CAVITATION ON  
CHEST XARY 
HIV   DIABETIC  SMOKING ALCOHOLIC 
DEFAULTER  RELAPSE 
TREATMENT 
FAILURE  
1 RAJAN 52 M ILLITERATE         NO NO yes NO  NO 
2 BABU 39 M ILLITERATE     RELAPSE   NO NO No NO  YES 
3 PALANIVEL 47 M ILLITERATE   DEFAULTER      NO NO No NO  YES 
4 PUSHPARAJ 48 M ILLITERATE   DEFAULTER      NO NO yes NO  YES 
5 DHANARAJ 53 M LITERATE   DEFAULTER      YES NO yes NO  YES 
6 JAYASHANKAR 41 M LITERATE 
New 
case       YES NO No NO  NO 
7 BOOPATHY 60 M ILLITERATE   DEFAULTER      YES NO yes NO  NO 
8 MANIVELAN 51 M LITERATE   DEFAULTER      NO NO No NO  NO 
9 RANGAN 54 M LITERATE   DEFAULTER      NO NO No NO  YES 
10 KALAISELVAM 64 M ILLITERATE   DEFAULTER      NO NO yes NO  YES 
11 CHANDRASEKAR 49 M LITERATE   DEFAULTER      NO NO No NO  YES 
12 NEELAKANDAN 54 M LITERATE   DEFAULTER      NO NO yes NO  YES 
13 VIJAYAKUMAR 50 M LITERATE     RELAPSE   NO NO yes NO  NO 
14 GUNASEELAN 49 M LITERATE   DEFAULTER      NO NO No NO  NO 
15 THIRUSEVAM 47 M ILLITERATE   DEFAULTER      NO NO No YES NO 
16 MOORTHY 50 M ILLITERATE   DEFAULTER      NO NO yes NO  NO 
17 ADHIMOOLAM 50 M ILLITERATE   DEFAULTER      NO NO yes NO  YES 
18 ARAVINDHAN 35 M LITERATE     RELAPSE   YES NO No NO  YES 
19 ANGAMUTHU 63 M ILLITERATE   DEFAULTER      NO NO yes YES YES 
20 MUTHUKUMARAN 51 M ILLITERATE     RELAPSE   NO NO No YES YES 
21 KUMARASAMY 60 M ILLITERATE   DEFAULTER      NO NO No YES YES 
22 SAMBANDHAM 69 M ILLITERATE       
TREATMENT 
FAILURE NO NO No NO  YES 
23 SEKAR 58 M ILLITERATE   DEFAULTER      NO NO yes YES NO 
24 SUBRAMANI 49 M LITERATE       
TREATMENT 
FAILURE NO NO No NO  YES 
25 MANIMARAN 56 M ILLITERATE   DEFAULTER      NO NO No NO  YES 
26 GOPALAN 69 M ILLITERATE       
TREATMENT 
FAILURE NO NO No NO  YES 
27 GOVINDAN 47 M ILLITERATE   DEFAULTER      YES NO yes YES YES 
 28 ELUMALAI 67 M LITERATE       
TREATMENT 
FAILURE NO NO No YES YES 
29 FIROZUDDIN 46 M ILLITERATE   DEFAULTER      NO NO No YES YES 
30 ISMAIL 52 M LITERATE     RELAPSE   NO NO No YES YES 
31 SAMINATHAN 64 M LITERATE   DEFAULTER      NO NO No YES YES 
32 ABDULLAH 51 M LITERATE     RELAPSE   NO NO yes NO  YES 
33 SHANMUGASUNDARAN 41 M ILLITERATE   DEFAULTER      NO NO No NO  YES 
34 SOUNDARAJAN 57 M ILLITERATE       
TREATMENT 
FAILURE NO NO No NO  YES 
35 IBAN 32 M LITERATE     RELAPSE   NO NO yes YES YES 
36 HARI 38 M ILLITERATE   DEFAULTER      YES NO yes NO  YES 
37 HAMEED ALI 39 M LITERATE     RELAPSE   NO NO No YES YES 
38 NAGARAJ 50 M LITERATE   DEFAULTER      YES NO No YES YES 
39 NANDAKUMAR 43 M LITERATE     RELAPSE   NO NO No YES YES 
40 NARAYANASAMY 71 M LITERATE   DEFAULTER      NO NO No NO  NO 
41 MANAVALAN 72 M LITERATE       
TREATMENT 
FAILURE NO NO No NO  NO 
42 MAHESHWARAN 31 M ILLITERATE   DEFAULTER      NO NO yes YES NO 
43 PARTHIBAN 28 M LITERATE     RELAPSE   YES NO No YES YES 
44 POOVARAN 46 M ILLITERATE   DEFAULTER      YES NO No YES NO 
45 RAJESH 29 M LITERATE   DEFAULTER      YES NO No NO  YES 
46 SAMEER 34 M LITERATE   DEFAULTER      YES NO No NO  NO 
47 SHEIK MOHAMMED 50 M ILLITERATE 
New 
case       NO NO No NO  NO 
48 DHANDAPANI 43 M LITERATE   DEFAULTER      NO NO No YES NO 
49 KAMALA 50 F LITERATE   DEFAULTER      NO NO No NO  YES 
50 KRISHNAVENI 52 F ILLITERATE     RELAPSE   NO NO yes NO  YES 
51 SIVAKUMAR 31 M ILLITERATE   DEFAULTER      YES NO No YES NO 
52 CHITRA 27 F ILLITERATE     RELAPSE   NO NO No NO  YES 
53 SHANTHA 47 F ILLITERATE   DEFAULTER      NO NO No NO  NO 
54 SELVAKUMAR 29 M LITERATE     RELAPSE   NO NO No YES YES 
55 GURUMOORTHY 49 M LITERATE   DEFAULTER      NO NO No YES YES 
56 TAMILSELVAN 46 M ILLITERATE     RELAPSE   NO NO yes YES NO 
57 SELVAKUMARI 47 F ILLITERATE   DEFAULTER      NO NO No NO  NO 
58 UMAPATHY 44 M LITERATE     RELAPSE   YES NO yes YES YES 
59 THANGAMANI 43 F ILLITERATE   DEFAULTER      YES NO No NO  YES 
60 RUKMANI 41 F LITERATE     RELAPSE   YES NO No NO  YES 
 61 GODHANDAN 44 M ILLITERATE   DEFAULTER      YES NO yes NO  YES 
62 KANNIYAPPAN 59 M ILLITERATE   DEFAULTER      NO NO yes NO  YES 
63 MURUGESAN 47 M ILLITERATE   DEFAULTER      NO NO No NO  YES 
64 PARTHASARATHY 39 M ILLITERATE   DEFAULTER      NO NO No NO  YES 
65 MUNIYANDI 48 M ILLITERATE       
TREATMENT 
FAILURE NO NO No NO  YES 
66 MUTHUKUMARAN 26 M LITERATE     RELAPSE   NO NO No NO  NO 
67 VADIVEL 32 M LITERATE     RELAPSE   NO NO No NO  NO 
68 VEERASAMY 53 M LITERATE   DEFAULTER      YES NO No YES NO 
69 DHANASEKAR 33 M ILLITERATE     RELAPSE   NO NO No YES YES 
70 KALIMUTHU 55 M ILLITERATE   DEFAULTER      NO NO No YES NO 
71 PICHANDI 63 M ILLITERATE   DEFAULTER      NO NO yes NO  YES 
72 PURUSOTHAMMAN 32 M ILLITERATE     RELAPSE   NO NO No NO  YES 
73 PACHAIYAPPAN 50 M ILLITERATE   DEFAULTER      NO NO No NO  NO 
74 THANGARASU 43 M ILLITERATE   DEFAULTER      YES NO No YES NO 
75 KANAGARAJ 40 M ILLITERATE 
New 
case       NO NO No YES NO 
76 MUBARAK ALI 41 M LITERATE   DEFAULTER      YES NO yes YES NO 
77 SENTHIL 36 M LITERATE     RELAPSE   YES NO No YES NO 
78 KALIYAMOORTHY 58 M LITERATE   DEFAULTER      YES NO yes YES YES 
79 GANESAN 32 M LITERATE     RELAPSE   YES NO No YES YES 
80 ANBARASU 29 M LITERATE   DEFAULTER      NO NO No YES YES 
81 PERIYASAMY 68 M ILLITERATE   DEFAULTER      NO NO No NO  YES 
82 JAYARAM 41 M ILLITERATE   DEFAULTER      NO NO No NO  YES 
83 SENTHILKUMAR 38 M ILLITERATE   DEFAULTER      YES NO No NO  YES 
84 SURESHKUMAR 26 M ILLITERATE     RELAPSE   NO NO No NO  NO 
85 SAMIKANNU 59 M ILLITERATE   DEFAULTER      YES NO yes NO  NO 
86 RAMKUMAR 23 M LITERATE     RELAPSE   NO NO No YES NO 
87 SATYAMOORTHY 44 M LITERATE   DEFAULTER      YES NO No YES NO 
88 MANIKANDAN 49 M ILLITERATE   DEFAULTER      YES NO yes NO  YES 
89 KRISHNAN 50 M LITERATE       
TREATMENT 
FAILURE YES NO No NO  YES 
90 LOGU 38 M ILLITERATE   DEFAULTER      NO NO No NO  NO 
91 SIVAKUMAR 36 M LITERATE   DEFAULTER      NO NO No NO  NO 
92 SUDHAKAR 38 M ILLITERATE   DEFAULTER      NO NO No NO  NO 
93 KUMAR 45 M LITERATE 
New 
case       NO NO No YES NO 
 94 RAMAN 37 M ILLITERATE   DEFAULTER      NO NO No YES NO 
95 MARIAMMAL 60 F ILLITERATE       
TREATMENT 
FAILURE NO NO yes YES NO 
96 SELVAM 44 M LITERATE   DEFAULTER      NO NO No YES NO 
97 PANNEERSELVAM 50 M ILLITERATE     RELAPSE   NO NO yes NO  NO 
98 ARUMUGAM 40 M LITERATE   DEFAULTER      YES NO No YES NO 
99 GOVINDARAJ 49 M LITERATE   DEFAULTER      YES NO yes NO  NO 
100 DEVAKI 59 F ILLITERATE       
TREATMENT 
FAILURE NO NO yes NO  NO 
101 DURAI 44 M LITERATE     RELAPSE   NO NO yes NO  YES 
102 VARADHARASU 57 M ILLITERATE       
TREATMENT 
FAILURE YES NO No NO  YES 
103 KANNAN 39 M ILLITERATE   DEFAULTER      NO NO yes NO  YES 
104 ANNADURAI 32 M ILLITERATE   DEFAULTER      NO NO No NO  NO 
105 RAJAMANIKAM 72 M LITERATE     RELAPSE   NO NO No NO  NO 
106 RAJAMMBAL 64 F LITERATE   DEFAULTER      YES NO No NO  NO 
107 RAJASEKAR 22 M ILLITERATE     RELAPSE   YES NO No NO  NO 
108 RAJAM 41 F ILLITERATE   DEFAULTER      NO NO No NO  NO 
109 MANI 34 M LITERATE   DEFAULTER      YES NO No NO  NO 
110 MUNIYANDI 68 M LITERATE   DEFAULTER      YES NO No NO  NO 
111 MUNUSAMI 54 M LITERATE   DEFAULTER      NO NO yes NO  NO 
112 SARAVANAN 32 M ILLITERATE     RELAPSE   NO NO No NO  NO 
113 MALAR 21 F ILLITERATE     RELAPSE   NO NO No NO  YES 
114 SANGEETHA 24 F ILLITERATE     RELAPSE   NO NO No NO  YES 
115 RUBY 35 F LITERATE     RELAPSE   YES NO yes NO  YES 
116 VALLI 46 F LITERATE   DEFAULTER      YES NO No NO  YES 
117 VANITHA 36 F LITERATE     RELAPSE   NO NO yes NO  YES 
118 CHITRA 37 F ILLITERATE     RELAPSE   YES NO No NO  YES 
119 PRIYANKA 26 F ILLITERATE     RELAPSE   YES NO yes NO  NO 
120 ARUNA 28 F LITERATE     RELAPSE   YES NO No NO  NO 
121 REVATHY 32 F LITERATE     RELAPSE   NO NO No NO  NO 
122 REGAVALLI 48 F LITERATE   DEFAULTER      NO NO No NO  NO 
123 USHA 41 F LITERATE   DEFAULTER      NO NO No NO  NO 
124 SUDHA 49 F ILLITERATE     RELAPSE   YES NO No NO  NO 
125 PANDYAMMA 54 F ILLITERATE   DEFAULTER      YES NO No NO  NO 
126 GANESAN 43 M ILLITERATE     RELAPSE   NO NO No NO  NO 
127 RAVIKUMAR 46 M ILLITERATE   DEFAULTER      NO NO yes NO  YES 
 128 SINGAMUL 41 M ILLITERATE     RELAPSE   NO NO No NO  YES 
129 SAILAJA 46 F ILLITERATE   DEFAULTER      YES NO No NO  YES 
130 RAGINI 41 F ILLITERATE     RELAPSE   YES NO No NO  YES 
131 KIRUBAKIRI 43 F ILLITERATE   DEFAULTER      NO NO yes NO  YES 
132 ANJALAI 39 F ILLITERATE   DEFAULTER      NO NO No NO  YES 
133 KOTHAI 45 F ILLITERATE   DEFAULTER      NO NO yes NO  NO 
134 SULOCHANA 50 F ILLITERATE   DEFAULTER      NO NO yes NO  NO 
135 PUNIDHA 39 F LITERATE       
TREATMENT 
FAILURE NO NO No NO  NO 
136 PACHAIYAMMAL 60 F ILLITERATE   DEFAULTER      NO NO yes NO  NO 
137 BATHMA 52 F LITERATE 
New 
case       NO NO No NO  YES 
138 RAJESWARI 41 F ILLITERATE 
New 
case       NO NO No NO  NO 
139 JOTHI 36 F ILLITERATE   DEFAULTER      NO NO No NO  NO 
140 BAKIYAM 57 F LITERATE   DEFAULTER      NO NO yes NO  NO 
141 KANNAMMAL 55 F ILLITERATE   DEFAULTER      NO NO yes NO  NO 
142 KASTHURI 56 F LITERATE   DEFAULTER      NO NO No NO  NO 
143 SAROJA 59 F LITERATE   DEFAULTER      NO NO yes NO  YES 
144 AMIRTHAVALLI 43 F LITERATE   DEFAULTER      NO NO No NO  YES 
145 RANJITHAM 48 F LITERATE   DEFAULTER      NO NO yes NO  YES 
146 RANIAMMAL 64 F ILLITERATE   DEFAULTER      NO NO yes NO  YES 
147 SEETHALAKSHMI 32 F LITERATE   DEFAULTER      NO NO No NO  NO 
148 MANIARASI 39 F LITERATE   DEFAULTER      NO YES No NO  NO 
149 CHELLAMMAL 66 F ILLITERATE   DEFAULTER      NO NO yes NO  NO 
150 PARAMESWARI 44 F LITERATE   DEFAULTER      NO NO yes NO  NO 
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  NEW  
CASE 
DEFAULTER  RELAPSE 
TREATMENT  
FAILURE  
1 SARAVANAN 42 M ILLITERATE     RELAPSE   NO NO NO NO NO 
2 CHELLADURAI 39 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
3 SUSEELAN 41 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
4 CHINNAMANI 48 M ILLITERATE   DEFAULTER      NO NO YES YES NO 
5 SELVARAJ 53 M ILLITERATE   DEFAULTER      NO NO NO NO YES 
6 ALAGIRI 41 M ILLITERATE   DEFAULTER      NO NO NO NO YES 
7 VASU 32 M ILLITERATE   DEFAULTER  RELAPSE   YES NO NO NO NO 
8 NATHAMUNI 51 M ILLITERATE   DEFAULTER      NO NO YES NO NO 
9 SURIYAPERUMAL 54 M LITERATE   DEFAULTER      NO NO NO YES NO 
10 KAVIARASU 40 M ILLITERATE   DEFAULTER      NO NO NO NO YES 
11 BOOPALAN 49 M LITERATE   DEFAULTER      YES NO NO NO NO 
12 MANIMARAN 54 M LITERATE       
TREATMENT 
FAILURE NO NO YES NO NO 
13 AROGYA DHASS 43 M ILLITERATE         NO NO NO NO NO 
14 ISAI SELVAN 32 M ILLITERATE   DEFAULTER      NO NO NO YES YES 
15 SARANGAM 47 M LITERATE   DEFAULTER  RELAPSE   NO NO YES NO NO 
16 SINGAMUTHU 50 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
17 ACHUDHANAND 42 M ILLITERATE   DEFAULTER      NO NO NO NO YES 
18 NANDHAGOPAL 35 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
19 PALLAVAN 63 M LITERATE   DEFAULTER      NO NO YES NO NO 
20 PERIYANDI 51 M ILLITERATE       
TREATMENT 
FAILURE NO NO NO YES YES 
21 SUBBURAYAN 60 M LITERATE   DEFAULTER      NO NO NO NO NO 
22 SUBRAMANI 69 M LITERATE     RELAPSE   YES NO YES NO NO 
23 MALLAN 58 M LITERATE   DEFAULTER      NO NO NO YES NO 
24 DILLIBABU 39 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
25 SYED ALI 56 M ILLITERATE   DEFAULTER      NO NO YES NO NO 
26 DAKSHINA 69 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
27 VIJAYAKUMAR 47 M ILLITERATE     RELAPSE   NO NO NO YES YES 
28 VIKRAM 23 M ILLITERATE   DEFAULTER      NO NO YES NO NO 
29 KARTHIKEYAN 39 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
 30 RAMMOORTHY 52 M ILLITERATE   DEFAULTER      NO NO NO NO YES 
31 JEYASHANKAR 64 M ILLITERATE   DEFAULTER      NO NO NO YES NO 
32 SANTHAKUMAR 31 M ILLITERATE   DEFAULTER      NO NO YES NO YES 
33 KUMARESAN 41 M LITERATE   DEFAULTER      NO NO NO NO NO 
34 SUDHAKARAN 41 M ILLITERATE   DEFAULTER      NO NO NO YES NO 
35 KARUNAKARAN 32 M ILLITERATE     RELAPSE   NO NO YES NO NO 
36 KATHIRVEL 38 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
37 PATTABIRAMAN 39 M LITERATE   DEFAULTER      NO NO NO NO NO 
38 THYAGARAJAN 50 M ILLITERATE   DEFAULTER      NO NO NO YES NO 
39 BAKIYANATHAN 43 M LITERATE   DEFAULTER      YES NO YES NO NO 
40 ADHIKESAVAN 71 M LITERATE     RELAPSE   NO NO NO NO YES 
41 SULAIMANN 72 M LITERATE   DEFAULTER      NO NO NO NO YES 
42 MOHAN 31 M LITERATE     RELAPSE   NO NO YES NO NO 
43 SUNDHARBABU 28 M LITERATE   DEFAULTER      NO NO NO YES NO 
44 MARIMUTHU 43 M LITERATE     RELAPSE   NO NO NO NO NO 
45 ANANDHARAJ 29 M ILLITERATE     RELAPSE   NO NO NO NO YES 
46 ARULSELVAM 34 M LITERATE   DEFAULTER      NO NO NO NO YES 
47 SIVAKUMAR 50 M ILLITERATE   DEFAULTER      NO NO YES NO NO 
48 PONNRASU 43 M LITERATE     RELAPSE   NO NO NO NO NO 
49 KRISHNA 32 M ILLITERATE     RELAPSE   NO NO NO NO NO 
50 BHARANI 52 M ILLITERATE     RELAPSE   NO NO NO YES NO 
51 ELANGOVAN 31 M ILLITERATE     RELAPSE   NO NO NO NO YES 
52 BASHA 27 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
53 NAGESWARAN 44 M ILLITERATE   DEFAULTER      YES NO NO NO NO 
54 PARAMESHWAR 29 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
55 SANTHANAM 39 M ILLITERATE   DEFAULTER      NO NO NO YES NO 
56 KOTI 46 M ILLITERATE     RELAPSE   NO NO NO NO YES 
57 JANARTHANAN 47 M LITERATE     RELAPSE   NO NO YES NO NO 
58 ARUN 44 M ILLITERATE   DEFAULTER      NO NO NO NO YES 
59 KUPPUSAMY 43 M ILLITERATE   DEFAULTER      NO NO YES NO NO 
60 KANRAYAN 41 M ILLITERATE     RELAPSE   NO NO NO NO YES 
61 JABARDHASS 44 M ILLITERATE     RELAPSE   NO NO NO NO NO 
62 LINGESWARAN 35 M ILLITERATE     RELAPSE   NO NO NO NO YES 
63 LOGANATHAN 47 M ILLITERATE   DEFAULTER      YES NO NO NO NO 
 64 MANICKAM 39 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
65 NITHYARAMAN 48 M LITERATE     RELAPSE   NO NO NO NO YES 
66 NAGARJUNAN 26 M ILLITERATE   DEFAULTER      NO NO NO NO NO 
67 HAMEED  32 M LITERATE   DEFAULTER      YES NO NO NO NO 
68 RIYAZ KHAN 39 M LITERATE       
TREATMENT 
FAILURE NO NO YES NO NO 
69 ASIF ALI 33 M LITERATE   DEFAULTER      NO NO NO NO YES 
70 IJAZ MOIDHEEN 55 M LITERATE   DEFAULTER      NO NO NO NO NO 
71 KALAIVANAN 29 M LITERATE   DEFAULTER      YES NO NO YES NO 
72 THILLAIRAJ 32 M LITERATE   DEFAULTER      NO NO YES NO NO 
73 RAJA 23 M LITERATE   DEFAULTER      NO NO NO NO NO 
74 BALAKRISHNAN  43 M LITERATE   DEFAULTER      NO NO NO NO NO 
75 DHANAPAL 40 M LITERATE   DEFAULTER      YES NO NO NO NO 
76 PREMNATH 41 M LITERATE   DEFAULTER      NO NO NO NO YES 
77 RAMALINGAM 36 M LITERATE   DEFAULTER      NO NO NO NO NO 
78 DEVARAJ 58 M LITERATE   DEFAULTER      NO NO YES NO NO 
79 ANNADURAI 48 M LITERATE     RELAPSE   NO NO NO NO YES 
80 VELURAJ 29 M LITERATE     RELAPSE   NO NO NO NO NO 
81 SETHURAMAN 68 M LITERATE     RELAPSE   NO NO NO YES YES 
82 JOTHI KRISHNAN 41 M LITERATE   DEFAULTER      YES NO NO NO NO 
83 CHANDRAN 38 M LITERATE   DEFAULTER      NO YES NO NO NO 
84 RAJA 26 M LITERATE     RELAPSE 
TREATMENT 
FAILURE NO NO NO NO NO 
85 SANTHINI 34 F LITERATE   DEFAULTER      NO NO YES NO YES 
86 KOTESWARI 23 F LITERATE   DEFAULTER      NO NO NO YES NO 
87 KOMALA 33 F LITERATE   DEFAULTER      NO NO NO NO YES 
88 KALAIVANI 26 F LITERATE   DEFAULTER      YES NO YES NO NO 
89 AMULU 44 F LITERATE   DEFAULTER      NO NO NO NO YES 
90 LALITHA 38 F LITERATE     RELAPSE   NO NO NO NO NO 
91 LOKESWARI 36 F LITERATE   DEFAULTER      NO NO NO NO YES 
92 SAMEERA BHANU 38 F LITERATE     RELAPSE   NO NO NO NO NO 
93 PUSHPALAKSHMI 45 F LITERATE   DEFAULTER      YES NO NO NO NO 
94 PANCHAVARNAM 37 F LITERATE   DEFAULTER      NO NO YES NO YES 
95 AMUDHA 28 F LITERATE   DEFAULTER      NO NO NO YES YES 
96 CHANDRAKALA 44 F LITERATE   DEFAULTER      YES NO NO NO NO 
 97 LAKSHMI 38 F LITERATE         NO NO NO NO NO 
98 LOGAMMAL 40 F ILLITERATE   DEFAULTER      NO NO YES NO YES 
99 VIJAYARANI 49 F LITERATE   DEFAULTER      NO NO NO NO NO 
100 SUJATHA 44 F LITERATE   DEFAULTER      NO NO NO NO NO 
101 SRIVANI 44 F LITERATE     RELAPSE   NO NO NO YES YES 
102 JEYASHREE 57 F ILLITERATE   DEFAULTER      NO NO NO NO NO 
103 AMBIKA 39 F LITERATE   DEFAULTER      NO NO YES NO NO 
104 AMARAVATHI 32 F LITERATE   DEFAULTER      NO NO NO YES NO 
105 ARULSELVI 21 F LITERATE   DEFAULTER      NO NO NO NO YES 
106 KALPANA 38 F LITERATE   DEFAULTER      NO NO NO NO YES 
107 KANAGAVALLI 22 F LITERATE   DEFAULTER      NO NO NO NO NO 
108 MENAGA 41 F LITERATE     RELAPSE   YES NO YES NO NO 
109 NOORJAHAN 34 F LITERATE   DEFAULTER      NO NO NO NO NO 
110 ASARAF FATHIMA 26 F LITERATE   DEFAULTER      NO NO NO NO NO 
111 MERY 54 F LITERATE   DEFAULTER      NO NO NO YES NO 
112 LATHA 32 F LITERATE   DEFAULTER      YES NO YES NO NO 
113 UMA 21 F LITERATE   DEFAULTER      NO NO NO NO NO 
114 SIVAKAM 46 F LITERATE   DEFAULTER      NO NO NO NO YES 
115 SAMPOORNA 35 F LITERATE   DEFAULTER      NO NO NO NO NO 
116 PAVITHRA 24 F LITERATE   DEFAULTER      YES NO NO YES NO 
117 RAJALAKSHMI 36 F LITERATE     RELAPSE   NO NO NO NO NO 
118 RAMADEVI 37 F LITERATE   DEFAULTER      NO NO YES NO NO 
119 DEIVANAI 32 F LITERATE   DEFAULTER      NO NO NO NO NO 
120 PREMA 28 F LITERATE   DEFAULTER      NO NO YES NO NO 
121 LEELAVATHY 32 F LITERATE   DEFAULTER      NO NO NO NO NO 
122 REKHALAKSHMI 31 F LITERATE   DEFAULTER      YES NO NO YES NO 
123 SIVASHAKTHI 41 F LITERATE   DEFAULTER      NO NO NO NO NO 
124 SURYAKALA 49 F LITERATE   DEFAULTER      NO NO NO NO NO 
125 SHEELA 30 F LITERATE     RELAPSE   NO NO NO NO YES 
126 JENABAAI 43 F LITERATE   DEFAULTER      NO NO NO YES NO 
127 YAMUNA 46 F LITERATE   DEFAULTER      YES NO NO NO NO 
128 GANGA 41 F LITERATE   DEFAULTER      NO NO NO NO YES 
129 JAMUNA 46 F LITERATE   DEFAULTER      NO NO NO NO NO 
130 PRABHA 41 F LITERATE   DEFAULTER      NO NO YES NO NO 
 131 PADHMINI 43 F LITERATE     RELAPSE   NO NO NO YES YES 
132 SUSEELAMMAL 56 F LITERATE   DEFAULTER      NO NO NO NO YES 
133 JANAKI 45 F LITERATE   DEFAULTER      NO NO NO NO NO 
134 VAIDHESWARI 50 F LITERATE   DEFAULTER      YES NO NO NO NO 
135 ANANDHI 39 F LITERATE     RELAPSE   NO NO NO YES NO 
136 SELVARANI 60 F LITERATE   DEFAULTER      NO NO NO NO NO 
137 SAVITHRI 52 F LITERATE   DEFAULTER      NO NO NO NO YES 
138 MULLAIRANI 41 F LITERATE   DEFAULTER      YES NO YES NO NO 
139 MANJULA 36 F LITERATE       
TREATMENT 
FAILURE NO NO NO NO NO 
140 GOMATHY 57 F LITERATE   DEFAULTER     NO NO YES NO NO 
141 HEMAVATHY 44 F LITERATE   DEFAULTER     NO NO NO NO YES 
142 SARALA 59 F LITERATE     RELAPSE   NO NO NO YES NO 
143 SILAMBARASI 39 F LITERATE   DEFAULTER     YES NO YES NO NO 
144 RASHIDHA 43 F LITERATE   DEFAULTER     NO NO NO NO NO 
145 FARIDHA 48 F LITERATE   DEFAULTER     NO NO NO NO YES 
146 PONNI 64 F LITERATE   DEFAULTER     YES NO NO NO NO 
147 VASANTHI 32 F LITERATE   DEFAULTER     NO NO NO NO NO 
148 DILLIRANI 39 F LITERATE     RELAPSE   NO NO NO NO NO 
149 PARIMALA 66 F LITERATE   DEFAULTER     NO NO NO YES YES 
150 DHAYALAMMAL 55 F LITERATE   DEFAULTER     YES NO YES NO NO 
 
